

CURRICULUM VITAE**GENERAL DATA**

SALMON, Isabelle

Place and date of birth:

Brussels (Belgium), June 08, 1959

Professional address:

Université Libre de Bruxelles
 Hôpital Erasme
 Laboratoire d'Anatomie-Pathologique
 808 Route de Lennik,
 B-1070 Bruxelles

Phone : 02/555 31 15

Fax : 02/555 47 90

E-mail: Isabelle.Salmon@erasme.ulb.ac.be

**EDUCATION**

- Second cycle: Doctor of Medicine (1985) great distinction, Université Libre de Bruxelles
- Third cycle: Specialist physician in Pathology (1991), Université Libre de Bruxelles
- Thesis of aggregation of Higher education (1993), Université Libre de Bruxelles: "
Contribution de la description quantitative du faciès chromatinien pour l'aide au diagnostic et au pronostic des tumeurs de la glande thyroïde et du système nerveux".

POSITIONS AND APPOINTMENTS

1985-91 Post-graduate physician, Pathology Department, Hôpital Erasme, Université Libre de Bruxelles.

1989-90 Research Grant of the Erasme Fonds, Université Libre de Bruxelles.

1991-94 Resident Physician, Pathology Department, Hôpital Erasme, Université Libre de Bruxelles.

1992 Training -Clinic Saint-Anne - Paris - France – Department of Neuropathology (Professor C. Daumas-Duport)

1993-96 Training-University of Virginia - Charlottesville - the USA - Department of Neuropathology (Professor S. VandenBerg)

1994-98 Assistant Clinical Head, Pathology Department, Hôpital Erasme, Université Libre de Bruxelles

1999 - Head of the Pathology Department, Hôpital Erasme, Université Libre de Bruxelles

2010- Director of the Research Center Inter Faculty, DIAPATH, Gosselies, Belgium

2011- Member of Académie Royale de Médecine de Belgique

TEACHING CAREER

1. Teaching: University courses:

- 2000- : ANAT068 (Seminars, Université Libre de Bruxelles)
- 2001- : ANAT015 – Theory (1st Master in Medicine, Université Libre de Bruxelles)
- 2001- : Course ANAT015 - Practical works (1st Master in Medicine, Université Libre de Bruxelles)
- 2001- : Participation in MEDI-G-410 – Neuropathology (Certificate of Neurology, 1st Master in Medicine, Université Libre de Bruxelles)
- 2002- : ANAT005 - (Anatomo-clinics confrontations, 3rd Master in Medicine, Université Libre de Bruxelles)
- 2006- : Participation in PROJ-H-500 (Ethics and current questions of medical engineering, 2nd Master Biomedical Civil engineer, Université Libre de Bruxelles)
- **2009: Regular professor, Surgical Pathology – ULB**

2. Teaching: other activities:

2.1 Teaching 3rd cycle:

- President of the Agreement Commission for training doctors in Pathology - Public Health, Safety of the Food Chain and Environment
- Vice-president of Complementary Master in Forensic medicine
- Member of the College of Teaching of Complementary Master in Medical Oncology
- Organization of Complementary Master in Pathology - interuniversity (ULG-UCL-ULB)
- President of Complementary Master in Anatomy Pathology Master of training course in Pathological anatomy

2.2 Teaching 2nd cycle:

- Master of training course of the Medical College of the Université Libre de Bruxelles
- Master in Medicine (MEDE4S with MEDE7S). Master of training course of the Faculty of

Sciences Applied of the Université Libre de Bruxelles

- Master in Biomedical Civil engineer (MA2).

2.3 Teaching High Schools:

- Master of training course, Haute Ecole Fransisco Ferrer in Brussels - Bachelor in Medical Biology (3rd year).
- Master of training course, Haute Ecole Charleroi-Fleurus, site ISC Fleurus - Bachelor in Medical Biology (3rd year).
- Master of training course, Haute Ecole Provinciale du Hainaut Occidental- site Tournai - Bachelor in executive secretary, medical option (3rd year).

2.4 Doctorate Theses in Medical sciences:

2.4.1 Promoter:

- Myriam Rimmelink (Thesis defended in 2002): Contribution à l'étude de la biologie des tumeurs des tissus mous: tumeurs des muscles lisses et tumeurs stromales gastro-intestinales (GISTs).
- Dr. Sandrine Rorive (Thesis defended in 2009): Les astrocytomes de bas grade: caractérisation moléculaire et implications cliniques.
- Dr. Nicky D' Haene (Thesis defended in 2011): Etude de l'implication des galectines 1 et 3 dans l'angiogenèse et en particulier en ce qui concerne les lymphomes.

2.4.2 Co-Promoter:

- Dr. Florence Lefranc (Thesis defended in 2004): Caractérisation de divers effets biologiques provoqués par la gastrine au niveau de gliomes et gliosarcomes expérimentaux.
- Dr. Niloufar Sadeghi (Thesis defended in 2011): Image based biomarkers for the in vivo evaluation of human brain gliomas.

2.4.3 Member of the jury of several Doctorate theses in Medical sciences

2.5 Promoter of DEA in Health Sciences:

- Myriam Rimmelink (graduate in 2000),
- Nathalie Nagy (graduate in 2003),
- Sandrine Rorive (graduate in 2003),
- Anne Mathieu (graduate in 2003),
- Nicky D' Haene (graduate in 2006),
- Calliope Maris (graduate in 2009).
- Anne-Laure Trépant (in progress).

2.6 Promoter of dissertation studies (Master of Pathology):

- Calliope Maris (2012),
- Nicky D'Haene (2010),
- Anne Mathieu (2006),
- Sandrine Rorive (2004),
- Brahim Eddafali (2003),
- Nathalie Nagy (2000),
- Myriam Rimmelink (1999).

2.7 Promoter and Co-promoter of Masters in Medicine:

Adelaïde Carlier (2012) Françoise Hulet (2011), Delphine Hastir (2011), Loiselet Lindsay (2011), Bartakova Alena (2011), Chadhed Afaf (2010) Anne-Laure Trépant (2010), Marine de Vicq de Cumptich (2010), Xavier Catteau (2007), Chloé D'Adesky (2007), Virginie Meurant (2006), Makrem Ben Khalifa (2006), Calliope Maris (2005), Nicky D' Haene (2004), Celine Grosjean (2003), Edward Boutremans (2003), Ingrid Beukinga (2001), Didier Frippiat (2000), Laurence Gordower (1998), Katty Delbecque (1996), Nathalie Nagy (1995), Myriam Rimmelink (1994)

2.8 Co-promoter of Masters in Biomedical Civil Engineer:

Xavier Moles Lopez (2008), Youness Jourani (2007).

2. Scientific activities

2.1. Member of:

- Société Belge d'Anatomie Pathologique (SBAP-BVPA)
 - * Member since 1993
 - * President 2008 -2011
 - * Past-President 2011-2012
- Belgian Week of Pathology (BWP):
 - * Member since 2005
 - * President since 2008 – 2011
 - * Past President 2011-2012
- British Division of the International Academy of Pathology (BDIAP) :
 - * Member since 2003
 - * Representing Belgium in the board since 2008-
 - * Nomination committee
- Belgian Brain Tumor Group (BBTG) :
 - * Founding Member since 2005
- European Association of Pathology Chairs and Program Directors (EAPCP) :
 - * Member since 2005
 - * Representing Belgium in the committee “Undergraduate training”
- Effective member in different societies :
 - * Société Belge de Cytologie (SBCC)
 - * Belgian Thyroid Cancer Study Group
 - * American Association for Cancer Research (AACR)
 - * Société Française de Neuropathologie (SFN)
 - * International Society of Neuropathology (ISN)
 - * New York Academy of Sciences
 - * Société Française d'Oncologie Pédiatrique (SFOP)
 - * Belgian Society of Neuroscience (BSN)
 - * United States and Canadian Academy of Pathology, Inc (USCAP)

2.2. Assignments with scientific journals and publishers : reviewer for:

- Acta Neurochirurgica,
- European Journal of Cancer
- European Urology

- Revue Médicale de Bruxelles
- Acta Neurologica Belgica
- Neurosurgery
- Oncogen
- British Journal of Dermatology
- Cancer Letters
- Acta Neuropathologica
- Cancer Epidemiology, Biomarkers & Prevention
- PLoS ONE
- Molecular and Cellular Endocrinology
- Clinical Endocrinology
- American Journal of pathology

2.3. Expert and/or consultant appointments:

- Scientific commission “Recherches Cliniques” du Fonds de la Recherche Scientifique Médicale (FRSM) : Effective member 2007 -2010
- Expert for Grant evaluation: Association for International Cancer Research Madras (United Kingdom)
- Companies: Roche , Astrazeneca, Pierre Fabre Médicaments, Samba Technologies TITN Alcatel for the european project Europath
- Ministry Office of Public Health, Food Chain Safety and Environment
 - * 2007-2008: participation in the drafting of the legal text published with the Belgian Monitor on December 19th, 2008 - Laws related to obtaining and the use of human body material intended for human medical applications or scientific research.
 - * 2006-2007: participation in the drafting of the Royal Decree relating to the agreement of the laboratories of Pathological Anatomy.
 - * Since 2004: member of the National Council Commission for evaluation of the voluntary interruption of pregnancy.
- KCE: Review of the National guidelines for testicular and thyroid cancers.

2.4. Other scientific activities (collaborations, patent applications, etc)

Granted patent :

EIZIRIK, Decio; FLAMEZ, Daisy; **SALMON, Isabelle**; BERTON, Alix; ROLAND, Isabelle; MARECHAL, Daniel; BECKERS, Marie-Claire; HOOD, Leroy; GOODMAN, Nathan; KUTLU, Burak.
PLASMA MEMBRANE BIOMARKERS PREFERENTIALLY EXPRESSED IN

PANCREATIC BETA CELLS USEFUL IN IMAGING OR TARGETING BETA CELLS.
WO/2009/101181; Publication Date: 20.08.2009

Patent application :

“Methods and diagnosis benign versus malignant thyroid lesions » filed in June 2009 (PCT/EP 2009/057744); Inventors: **Salmon I**, Belayew A, Capouillez A, Paci P, Saussez S, Decaestecker C.

3. Activities in the frame of co-operation for development

- Responsible of the complete training in pathology for doctors within the framework of the co-operation with Gabon (Corinne Engohan).
- Co-promoter of the Doctorate thesis in Medical sciences of Doctor Jean-Marie Kabongo Mpolesha of the Medical College of the University of Kinshasa: profil anatomo-clinique et immunohistochimique des lymphomes en République Démocratique du Congo.
- Responsible of the training courses in pathology for doctors within the framework of collaboration with Belgian technical collaboration (CTB) (Democratic Republic of Congo, Mali,).
- Host Laboratory for many visiting doctors.

Logistics responsibilities:

1. Within the framework of teaching and research

1.1. Responsibility for centers, research groups, scientific and pharmaceutical companies

- Obtention and management of number of contracts with the Pharmaceutical Companies (AstraZeneca, Merck, Bayer, Novartis Pharma, Shering Plough, Janssen-Cilag, Aventis Pharma, GlaxoSmithKline, Transgene, Eli Lilly and Co, 3M Belgium SA, Fujisawa GmbH, Antigenics, Rhone-Poulenc, Roche) within the framework of the clinical research in the pathology department of Erasme Hospital.
- Fonds Yvonne Boël Administrator since 1999.
- Promoter and Co-promoter of Research Credits:
 - * Credit “Fonds de la Recherche Scientifique Médicale” (n° 3.4501.95) ;
 - * Credit « Télévie 1995 » (n° 7.4547.95) ;

- * Credit « Télévie 1996 » (n° 7.4511.96) ;
- * Project EUROPATH des Communautés Européennes (1996-1998) ;
- * Credit « Télévie 1997 » (n° 7.4525.97) ;
- * Credit « Télévie 1998 » (n° 7.4502.98) ;
- * Credit « Fonds de la Recherche Scientifique Médicale » (n° 3.4511.99) ;
- * Credit « Télévie 1999 » (n° 7.4504.99) ;
- * Credit « Fondation Yvonne Boël » ;
- * Credit « Télévie 2000 » (n° 7.4527.00) ;
- * Convention « Fonds de la Recherche Scientifique Médicale » 1997-2000
(n° 9.4.508.97.F) ;
- * Convention « Télévie » octobre 1999 – octobre 2003 (n° 7.4.504.99) ;
- * Convention « Fonds de la Recherche Scientifique Médicale » 2002-2005
(n° 3.4.582.02.F) ;
- * Convention « Télévie » (n° 7.4.580.02.F) ;
- * Convention « Fonds de la Recherche Scientifique Médicale » 2004-2007
(n° 3.4614.04.F) ;
- * Convention « Région Wallonne – Pôle de compétitivité « Sciences du vivant » -
Keymarker » 2006-2010 (n°5437) ;
- * Convention « Registre du Cancer – Bio-Bank » 2008-2009.
- * Convention “Télévie” octobre 2009 – octobre 2011 (n°7.4.511.09F);
- * Credit 2010 « Fonds National de la Recherche Scientifique » (n°1.A493.10).

1.2. Host Laboratory for summer internship within the framework of the University of Yale (New Haven, the USA) “Bulldogs” program.

1.3. Organization of congress and conferences (national or international)

- Organization of post-graduated courses in pathology within the framework of the Belgian Society of Pathology (SBAP);
- Organization of Belgian Week of Pathology ;
- Organization of the technical courses within the framework of the “Association Nationale Française des Technologistes en Anatomie et Cytologie Pathologiques (ACP France) ».

LOGISTICS RESPONSIBILITIES:

Within the framework of teaching and research**- Responsibility for centers, research groups, scientific and pharmaceutical companies**

- Obtention and management of number of contracts with the Pharmaceutical Companies (AstraZeneca, Merck, Bayer, Novartis Pharma, Shering Plough, Janssen-Cilag, Aventis Pharma, GlaxoSmithKline, Transgene, Eli Lilly and Co, 3M Belgium SA, Fujisawa GmbH, Antigenics, Rhone-Poulenc, Roche) within the framework of the clinical research in the pathology department of Erasme Hospital.
- Fonds Yvonne Boël Administrator since 1999.
- Promoter and Co-promoter of Research Credits:
 - * Credit “Fonds de la Recherche Scientifique Médicale” (n° 3.4501.95) ;
 - * Credit « Télévie 1995 » (n° 7.4547.95) ;
 - * Credit « Télévie 1996 » (n° 7.4511.96) ;
 - * Project EUROPATH des Communautés Européennes (1996-1998) ;
 - * Credit « Télévie 1997 » (n° 7.4525.97) ;
 - * Credit « Télévie 1998 » (n° 7.4502.98) ;
 - * Credit « Fonds de la Recherche Scientifique Médicale » (n° 3.4511.99) ;
 - * Credit « Télévie 1999 » (n° 7.4504.99) ;
 - * Credit « Fondation Yvonne Boël » ;
 - * Credit « Télévie 2000 » (n° 7.4527.00) ;
 - * Convention « Fonds de la Recherche Scientifique Médicale » 1997-2000 (n° 9.4.508.97.F) ;
 - * Convention « Télévie » octobre 1999 – octobre 2003 (n° 7.4.504.99) ;
 - * Convention « Fonds de la Recherche Scientifique Médicale » 2002-2005 (n° 3.4.582.02.F) ;
 - * Convention « Télévie » (n° 7.4.580.02.F) ;
 - * Convention « Fonds de la Recherche Scientifique Médicale » 2004-2007 (n° 3.4614.04.F) ;
 - * Convention « Région Wallonne – Pôle de compétitivité « Sciences du vivant » - Keymarker » 2006-2010 (n°5437) ;
 - * Convention « Registre du Cancer – Bio-Bank » 2008-2009.
 - * Convention “Télévie” octobre 2009 – octobre 2011 (n°7.4.511.09F);
 - * Credit 2010 « Fonds National de la Recherche Scientifique » (n°1.A493.10).

- Host Laboratory for summer internship within the framework of the University of Yale (New

Haven, the USA) “Bulldogs” program.

- Organization of congress and conferences (national or international)

- Organization of post-graduated courses in pathology within the framework of the Belgian Society of Pathology (SBAP);
- Organization of Belgian Week of Pathology ;
- Organization of the technical courses within the framework of the “Association Nationale Française des Technologistes en Anatomie et Cytologie Pathologiques (ACP France) ».

PUBLICATIONS

Part of collective works

1. Intramedullary spinal cord tumors. 110 pages. Masson. 1994. G. Fisher.
2. Glycosciences. Status and Perspectives. 631 pages. Chapman & Hall, Weinheim. 1997. HJ. Gabius.
3. Radiosurgery and pathological fundamentals. Progress in Neurological Surgery. 400 pages. L.D. Lunsford. 2004. GT. Szeifert.
4. Traité de Médecine Légale. 837 pages. De Boeck. 2007. JP. Beauthier.

Articles in international scientific journals with lecture committee

1990

1. Gevenois PA, **Salmon I**, Stallenberg B, Van Sinoy ML, Van Regermorter G, Struyven J: MR Imaging of the normal prostate at 1.5 Tesla. Br J Radiol. 1990;63:101-7. IF = 1.0.
2. Verhest A, Kiss R, d’Olné D, Larsimont D, **Salmon I**, de Launoit Y, Fourneau C, Pasteels JL, Pector JC. Characterization of human colorectal mucosa, polyps and cancers by means of computerized morphonuclear image analyses. Cancer 1990;65: 2047-2054. IF = 3.6.
3. Gevenois PA, Van Sinoy ML, Sintzoff SA Jr, Stallenberg B, **Salmon I**, Van Regermorter G, Struyven J. Cysts of the prostate and seminal vesicles: MR imaging findings in 11 cases. Am J Radiol 1990,155:1021-1024. IF = 2.1.

1991

4. Collin F, **Salmon I**, Rahier I, Pasteels JL, Heimann R, Kiss R. Quantitative nuclear cell image analyses of thyroid tumors from archival material. Hum Pathol. 1991;22:191-196. IF = 2.9.
5. **Salmon I**, Coibion M, Larsimont D, Badr-El-Din H, Verhest A, Pasteels JL, Kiss R. Comparison of fine needle aspirates of breast cancers to imprint smears by means of digital cell image analysis. Anal Quant Cytol Histol. 1991;13: 193-200. IF = 0.9.
6. Kiss R, **Salmon I**, Pauwels O, Gras S, Danguy A, Etiévant C, Pasteels JL, Martinez J. In vitro influence of gastrin, oestradiol and gonadotropin-releasing hormone on HCT-15 and LoVo human colorectal neoplastic cell proliferation. Eur J Cancer 1991;27: 1268-1274. IF = 2.7.

7. De Waele M, Renmans W, Segers E, Jochmans K, **Salmon I**, Depardieu C, Dehou F, Van Camp B: Leukemia and lymphoma immunophenotyping in cell smears with immunogold-Silver staining. *Am J Clin Pathol* 1991;96:351-359. IF = 2.9.

1992

8. **Salmon I**, Kiss R, Franc B, Gasperin P, Heimann R, Pasteels JL, Verhest A. Comparison of morphonuclear features in normal, benign, and neoplastic thyroid tissue by digital cell image analysis. *Anal Quant Cytol Histol* 1992;14: 47-54. IF = 0.9.

9. **Salmon I**, Kiss R, DeWitte O, Gras T, Pasteels JL, Brotchi J, Flament-Durand J. Histopathologic grading and DNA ploidy in relation to survival among 206 adult astrocytic tumor patients. *Cancer* 1992;70: 538-546. IF = 3.6.

10. **Salmon I**, Gasperin P, Pasteels JL, Heimann R, Kiss R. Relationship between histopathologic typing and morphonuclear assessments of 238 thyroid lesions. Digital cell image analysis performed on Feulgen-stained nuclei from formalin-fixed, paraffin-embedded materials. *Am J Clin Pathol* 1992;97: 776-786. IF = 2.9.

11. Geveno PA, Stallenberg B, Sintzoff SA, **Salmon I**, Van Regermorter G, Struyven J: Granulomatous prostatitis: a pitfall in MR imaging of prostatic carcinoma. *Eur Radiol* 1992;2:365-367. IF = 1.1.

1993

12. **Salmon I**, Kiss R. Relationship between proliferative activity and ploidy level in a series of 530 human brain tumors including astrocytomas, meningiomas, schwannomas and metastases. *Hum Pathol* 1993;24:329-335. IF = 2.9.

13. **Salmon I**, Kiss R, Levivier M, Rummelink M, Pasteels JL, Brotchi J, Flament-Durand J. Characterization of nuclear DNA content, proliferation index, and nuclear size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors. *Am J Surg Pathol* 1993;17:239-247. IF = 2.1.

14. Kiss R, **Salmon I**, Camby I, Gras S, Pasteels JL. Characterization of factors in routine laboratory protocols that significantly influence the Feulgen reaction. *J Histochem Cytochem* 1993;41:935-945. IF = 2.6.

15. Dangou JM, **Salmon I**, Torres LFB, Budel V, Demba Ndiaye P, Pasteels JL, Verhest A, Kiss R. DNA histogram typing in retinoblastomas and neuroblastomas. *Modern Pathol* 1993;6:408-413. IF = 3.2.

16. **Salmon I**, Gasperin P, Rummelink M, Rahier I, Rocmans P, Pasteels JL, Heimann R, Kiss R. Ploidy level and proliferative activity measurements in a series of 407 thyroid tumors or other pathologic conditions. *Hum Pathol* 1993;24: 912-920. IF = 2.9.

17. **Salmon I**, Kruczynski A, Camby I, Levivier M, Pasteels JL, Brotchi J, Kiss R. DNA histogram typing in a series of 707 tumors of the central and peripheral nervous system. *Am J Surg Pathol* 1993;17:1020-1028. IF = 4.3

18. Yeaton P, Kiss R, Devière J, **Salmon I**, Bourgeois N, Pasteels JL, Cremer M. Clinical utility of cell image analysis in the detection of cancer from specimens obtained during endoscopic retrograde cholangiopancreatography. *Am J Clin Pathol* 1993;100:497-501. IF = 2.9.

19. **Salmon I**, Levivier M, Camby I, Rombaut K, Gras T, Pasteels JL, Brotchi J, Kiss R. Assessment of nuclear size, nuclear DNA content and proliferation index in stereotaxic biopsies

from brain tumours. *Neuropathol Appl Neurobiol* 1993;19:507-518. IF = 2.5.

20. Kinnaert P, **Salmon I**, Decoster-Gervy C, Bergman P, Hooghe L, De Pauw L, Van Geertruyden J. Total parathyroidectomy and presternal subcutaneous implantation of parathyroid tissue for renal hyperparathyroidism. *Surg Gynecol Obstet* 1993;176:135-138. IF = /.

1994

21. **Salmon I**, DeWitte O, Pasteels JL, Flament-Durand J, Brotchi J, Vereerstraeten P, Kiss R. Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. *J Neurosurg* 1994;80:877-883. IF = 2.9

22. Rummelink M, **Salmon I**, Petein M, Gras T, Zandona C, Pasteels JL, Kiss R. Determination of DNA ploidy, nuclear size and proliferative activity by means of the computer-assisted image analysis of Feulgen-stained nuclei in 68 soft tissue tumors of adults. *Hum Pathol* 1994;25:694-701. IF = 2.9.

23. **Salmon I**, Camby I, Gras T, Rombaut K, Pasteels JL, Kiss R. The use of digital cell image analysis of Feulgen-stained nuclei to quantitatively describe morphonuclear features in a series of 174 meningiomas. *Modern Pathol* 1994;7: 570-577. IF = 3.2.

24. Camby I, **Salmon I**, Rorive S, Gras T, Darro F, Kruczynski A, Danguy A, Pasteels JL, Kiss R. Characterization of the influence of anti-hormone and/or anti-growth factor neutralizing antibodies on cell clone architecture and the growth of human neoplastic astrocytic cell lines. *J Neuro-Oncol* 1994;20: 67-80. IF = 1.6.

25. Rummelink M, **Salmon I**, Petein M, Henrion S, Pasteels JL, Kiss R. Computer-assisted quantitative description of chromatin pattern in soft tissue tumors of the adult. *Am J Clin Pathol* 1994;102:780-787. IF = 2.9.

26. Robberecht P, Woussen-Colle MC, Vertongen P, De Neef P, Hou X, **Salmon I**, Brotchi J. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. *Peptides* 1994;15:661-665. IF = 2.6.

1995

27. **Salmon I**, Swan I Jr, Dargent JL, Pasteels JL, Kiss R, Katz R. Relationship between DNA ploidy level, nuclear size and survival in large cell lymphoma. *Am J Clin Pathol* 1995;103:568-573. IF = 2.9.

28. Decaestecker C, **Salmon I**, Camby I, DeWitte O, Pasteels JL, Brotchi J, Van Ham Ph, Kiss R. Identification of high versus lower risk clinical subgroups in a group of adult patients with supratentorial anaplastic astrocytomas. *J Neuropathol Exp Neurol* 1995;54:371-384. IF = 5.6.

29. Kiss R, Camby I, **Salmon I**, Van Ham Ph, Brotchi J, Pasteels JL. Relationship between DNA ploidy level and tumor sociology behavior in 12 nervous cell lines. *Cytometry* 1995;20:118-126. IF = 2.6.

30. Rummelink M, **Salmon I**, Pasteels JL, Ardichvili D, Kiss R. Nuclear DNA content, proliferation index, and nuclear size determination in normal and tumoral adrenal tissues, pheochromocytomas, and metastases. *Acta Cytologica* 1995;39:416-422. IF = 1.4.

31. Kiss R, **Salmon I**, Kruczynski A, Camby I, Pasteels JL, Van Ham P. Aneuploidy occurrence

in human tumours: a logical-automaton approach. *Anal Cell Pathol* 1995;9:95-111. IF = 0.8.

32. Yeaton P, Kiss R, DePrez C, **Salmon I**, Pasteels JL, Jones RS, Frierson H Jr. Multiparameter digital image analysis of biliary, ampullary and pancreatic adenocarcinomas. *Modern Pathol* 1995;8:843-847. IF = 2.9.

33. **Salmon I**, Rorive S, Camby I, Decaestecker C, Pirotte B, Rombaut K, Haot J, Pasteels JL, Brotchi J, Kiss R. Stereotactic biopsies from astrocytic tumors: Diagnostic information contributed by the quantitative chromatin pattern description. *Anal Quant Cytol Histol* 1995;7:332-343. IF = 0.9.

34. Camby I, **Salmon I**, Danguy A, Pasteels JL, Kiss R. The use of the digital cell image analysis of Feulgen-stained nuclei to detect apoptosis. *Histochem & Cell Biol* 1995;104:407-414. IF = 2.2.

1996

35. Kiss R, Rorive S, Camby I, Pasteels JL, Brotchi J, **Salmon I**. DNA ploidy level assessments in 83 human brain metastases. Relationship to the survival of 35 patients. *J Cancer Res Clin Oncol*.1996;122:127-131. IF = 1.8.

36. Rummelink M, **Salmon I**, Goldschmidt D, Decaestecker C, Nemeč E, Berthe JV, Petein M, Pasteels JL, Kiss R. The value of nuclear DNA and texture analysis by digital image processing in the diagnosis of lipomatous and leiomyomatous tumours. *Anal Cell Pathol*. 1996;10:45-58. IF = 0.8.

37. **Salmon I**, Camby I, Rummelink M, Rombaut K, Pasteels JL, Brotchi J, Kiss R, Danguy A. Lectin histochemistry, ploidy level and proliferation indices in meningioma subtypes. *Neuropathol Appl Neurobiol*. 1996;22:68-76. IF = 2.5.

38. Decaestecker C, van Velthoven R, Petein M, Janssen T, **Salmon I**, Pasteels JL, van Ham P, Schulman C, Kiss R. The use of the decision tree technique and image cytometry to characterize aggressiveness in World Health Organization (WHO) grade II superficial transitional cell carcinomas of the bladder. *J Pathol*. 1996;178:274-283. IF = 4.1.

39. Camby I, **Salmon I**, Danguy A, Pasteels JL, Kiss R. Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines. *J Neurooncol*. 1996;28:1-11. IF = 1.6.

40. Camby I, **Salmon I**, Bourdel E, Nagy N, Danguy A, Brotchi J, Pasteels JL, Martinez J, Kiss R. Neurotensin-mediated effects on astrocytic tumor cell proliferation. *Neuropeptides* 1996;30:133-139. IF = 1.4.

41. Decaestecker C, Rummelink M, **Salmon I**, Camby I, Goldschmidt D, Petein M, Van Ham P, Pasteels JL, Kiss R. Methodological aspects of using Decision Trees to characterise leiomyomatous tumors. *Cytometry* 1996;24:83-92. IF = 2.6.

42. Camby I, **Salmon I**, Danguy A, Pasteels JL, Brotchi J, Martinez J, Kiss R. Influence of gastrin on human astrocytic tumor cell proliferation. *J Natl Cancer Inst*.1996;88:594-600. IF = 14.2.

43. Frierson HF Jr., Wilbur DC, Gaffey MJ, **Salmon I**, Franquemont DW, Berean KW, Wolber RA, Kiss R. Quantitative image cytometry of infiltrating ductal carcinoma: comparison to prognostic parameters and reproducibility of histological grade. *Hum Pathol*. 1996;27:821-826. IF = 2.9

44. Hassid S, **Salmon I**, Bovin N, Kiss R, Gabius HJ, Danguy A. Histochemical detection of binding sites for labelled hyaluronic acid and carrier-immobilized synthetic (histo-blood group trisaccharides) or biochemically purified (ganglioside GM1) in nasal polyps and other human lesions including neoplasms. *Histol Histopathol.* 1996;11:985-992. IF = 1.6
45. Berthe JV, Goldschmidt D, **Salmon I**, Decaestecker C, Rummelink M, Petein M, Pasteels JL, Roels H, Frierson H Jr, Kiss R.. Image cytometry analysis of Feulgen-stained nuclei in 72 lipomatous lesions including atypical lipomas and well-differentiated liposarcomas. *Am J Clin Pathol* 1996;106:289-297. IF = 2.9.
46. Goldschmidt D, Decaestecker C, Berthe JV, Gordower L, Rummelink M, Danguy A, Pasteels JL, **Salmon I**, Kiss R. The contribution of image cytometry and artificial intelligence-related methods of numerical data analysis for adipose tumor histopathologic classification. *Lab Invest.* 1996;75:295-306. IF = 4.2.
47. De Witte O, Levivier M, Violon P, **Salmon I**, Damhaut P, Wikler D Jr, Hildebrand J, Brotchi J, Goldman S. Prognostic value positron emission tomography with (18F)fluoro-2-deoxy-D-glucose in the low-grade glioma. *Neurosurgery* 1996;39:470-476. IF = 2.9.
48. Camby I, **Salmon I**, Oiry C, Galleyrand JC, Nagy N, Danguy A, Brotchi J, Pasteels JL, Martinez J, Kiss R. The influence of gastrin and/or cholecystokinin antagonists and agonists on the proliferation of three human astrocytic tumor cell lines. *Neuropeptides* 1996;30:433-437. IF = 1.4.
49. Rummelink M, **Salmon I**, Goldschmidt D, Decaestecker C, Nemecek E, Berthe JV, Petein M, Pasteels JL, Kiss R. Quantitative measurements of desmin and vimentin immunostains and cell density in leiomyomas and leiomyosarcomas. *Anal Cell Pathol.* 1996;12:25-44. IF = 0.8.
50. Kinnaert P, DeWilde JP, Bournonville B, Husson C, **Salmon I**. Direct activation of human peritoneal mesothelial cells by heat-killed microorganisms. *Ann Surg.* 1996;224:749-755. IF = 6.0.
- 1997**
51. Kiss R, Dewitte O, Decaestecker C, Camby I, Gordower L, Delbecque K, Pasteels JL, Brotchi J, **Salmon I**. The combined determination of proliferative activity and cell density in the prognosis of adult patients with supratentorial high-grade astrocytic tumors. *Am J Clin Pathol.* 1997;107:321-331. IF = 2.9.
52. Kiss R, Camby I, Duckworth C, DeDecker R, **Salmon I**, Pasteels JL, Danguy A, Yeaton P. In vitro influence of Phaseolus vulgaris, Griffonia simplicifolia, Concanavalin A, wheat germ, and peanut agglutinins on HCT-15, LoVo, and SW837 human colorectal cancer cell growth. *Gut.* 1997;40:253-261. IF = 5.4.
53. Decaestecker C, **Salmon I**, DeWitte O. Camby I, Van Ham Ph, Pasteels JL, Brotchi J, Kiss R. Nearest-neighbor classification for identification of aggressive versus nonaggressive low-grade astrocytic tumors by means of image cytometry-generated variables. *J Neurosurg.* 1997;86:532-537. IF = 2.9.
54. Hassid S, **Salmon I**, Brugmans M, Dawance S, Kiss R, Gabius HJ, Danguy A. Histochemical study of the epithelia of nasal polyps by biotinylated lectins and neoglycoproteins. A comparison with the normal human respiratory epithelium. *Eur J Morphol.* 1997;35:77-85. IF = 0.8.
55. DeHauwer C, Camby I, Darro F, Decaestecker C, Gras T, **Salmon I**, Kiss R. Van Ham Ph. Dynamic characterization of glioblastoma cell motility. *Biochem Biophys Res Commun.* 1997;232:267-272. IF = 3.0.

56. Decaestecker C, Lopes BS, Gordower L, Camby I, Cras P, Martin JJ, Kiss R, Vandenberg SR, **Salmon I**. Quantitative chromatin pattern description in Feulgen-stained nuclei as a diagnostic tool to characterize the oligodendroglial and astroglial components in mixed oligo-astrocytomas. *J Neuropathol Exp Neurol*. 1997;56:391-402. IF = 5.6.
57. Lopes MB, **Salmon I**, Nagy N, Decaestecker C, Pasteels JL, Laws ER Jr, Kiss R. Computer-assisted microscope analysis of Feulgen-stained nuclei in gonadotrophs as opposed to null-cell adenomas. *Endocrine Pathol*. 1997;8:109-120. IF = 0.4.
58. D. Goldschmidt, L. Gordower, JV. Berthe, M. Rummelink, C. Decaestecker, M. Petein, I. Salmon, R. Kiss, A. Danguy. Contribution of quantitative lectin histochemistry to characterizing well-differentiated, dedifferentiated and poorly differentiated liposarcomas. *Anal Quant Cytol Histol.*, 19 (1997), 215-226. IF = 0.9
59. Camby I, Nagy, Rombaut K, Gras T, Duponchelle C, Pasteels JL, Brotchi J, Kiss R, **Salmon I**. Influence of epidermal growth factor and gastrin on the cell proliferation of human meningiomas versus astrocytic tumors maintained as ex vivo tissue cultures. *Neuropeptides* 1997;31:217-225. IF = 1.4.
60. Decaestecker C, Camby I, Rummelink M, Nagy N, Petein M, Pasteels JL, Van Ham P, **Salmon I**, Kiss R. Decision tree induction: a useful tool for assisted diagnosis and prognosis in tumor pathology. *Lab Invest*. 1997;76:799-808. IF = 4.2
61. Camby I, **Salmon I**, De Decker R, Pasteels JL, Brotchi J, Danguy A, Kiss R. Lectin histochemistry of astrocytic tumors and in vitro characterization of lectin-induced modifications of the proliferation of the SW1088, U373 and U87 human astrocytic cell lines. *J Neuro-Oncol*. 1997;34:111-122. IF = 1.6.
62. Renard N, Goldschmidt D, Decaestecker C, Lorea P, Berthe JV, Verraes S, Ghanem G, **Salmon I**, Kiss R. Characterization of the nuclear deoxyribonucleic acid content and nuclear morphometry in 71 primary cutaneous melanomas. *Dermatology* 1997;194:318-324. IF = 0.9.
63. Budel V, Gasperin P, Hatschbach S, Cavalcanti TC, Pétein M, Decaestecker C, Darro F, **Salmon I**, Kiss R. Ploidy level determination and quantitative chromatin pattern description in pregnancy-associated breast cancers. *Breast Cancer Res Treat*. 1997;45:109-120. IF = 2.7.
64. François C, Decaestecker C, Petein M, van Ham P, Peltier A, Pasteels JL, Danguy A, **Salmon I**, van Velthoven R, Kiss R. Classification strategies for the grading of renal cell carcinomas, based on nuclear morphometry and densitometry. *J Pathol*. 1997;183:141-150. IF = 4.1.
65. Pirotte B, Goldman S, David P, Wikler D, Damhaut P, Vandesteene A, Salmon L, Brotchi J, Levivier M. Stereotactic brain biopsy guided by positron emission tomography (PET) with 18F-fluorodeoxyglucose and 11C-methionine. *Acta Neurochir Suppl*. 1997;68:133-138. IF = 0.8.
66. Hassid S, Degaute MP, Dawance S, Rombaut K, Nagy N, Choufani G, Decaestecker C, Danguy A, **Salmon I**, Kiss R. Determination of proliferative activity in nasal polyps. *J Clin Pathol*. 1997;50: 923-928. IF = 1.7.
67. Loréa P, Decaestecker C, Goldschmidt D, Renard N, André J, Lipski D, Van den Heule B, **Salmon I**, Darro F, Kiss R. Correlation between gender and cytomorphonuclear characteristics as revealed by computer-assisted microscope analysis of Feulgen-stained nuclei in 69 human melanomas. In vitro evidence of sex steroid-induced modifications in the morphonuclear characteristics of 3 human melanoma cell lines. *Melanoma Res*. 1997;7:382-392. IF = 1.9.
68. Hassid S, Decaestecker C, Hermans C, **Salmon I**, Pasteels JL, Danguy A, Kiss R. Lectin

glycohistochemical and Feulgen cytometrical characteristics analyzed using an artificial intelligence-related algorithm to propose a new histoclinical classification for nasal polyposis. *Ann Otol, Rhinol & Laryngol.* 1997;106:1043-1051. IF = 1.1.

69. Loréa P, Goldschmidt D, Darro F, **Salmon I**, Bovin N, Gabius HJ, Kiss R, Danguy A. In vitro characterization of lectin-induced alterations on the proliferative activity of three human melanoma cell lines. *Melanoma Res.* 1997;7:353-363. IF = 1.9

1998

70. Decaestecker C, Camby I, Nagy N, Brotchi J, Kiss R, **Salmon I**. Improving morphology-based malignancy grading schemes in astrocytic tumors by means of computer-assisted techniques. *Brain Pathol.* 1998;8:29-38. IF = 6.4.

71. Saussez S, Marchant H, Nagy N, Decaestecker C, Hassid S, Jortay A, Schüring MP, Gabius HJ, Danguy A, **Salmon I**, Kiss R. Quantitative glycohistochemistry defines new prognostic markers in cancers of the oral cavity. *Cancer* 1998;82:252-260. IF = 3.6.

72. Kiss R, Decaestecker C, Camby I, Darro F, **Salmon I**, Danguy A, Pasteels JL, Yeaton P. Evidence of a direct relationship between hormone-sensitivity level and growth pattern in 19 gastrointestinal neoplastic cell lines. *Anal Quant Cytol Histol.* 1998; 20:133-143. IF = 0.9.

73. Sears RJ, Duckworth CW, Decaestecker C, Bourgeois N, Ledent T, Deviere J, **Salmon I**, Kiss R, Yeaton P. Image cytometry as a discriminatory tool for cytologic specimens obtained by endoscopic retrograde cholangiopancreatography. *Cancer* 1998;84:119-126. IF = 3.6.

74. François C, Decaestecker C, **Salmon I**, Péteïn M, Rimmelink M, Janssen T, Peltier A, Wespes E, Schulman C, van Velthoven R, Kiss R. Prognostic value of stem cell line identification for renal cell carcinoma. *Anal Quant Cytol Histol.* 1998;20:207-214. IF = 0.9.

75. Rimmelink M, Decaestecker C, Darro F, Goldschmidt D, Gebhart M, Pasteels JL, Kiss R, **Salmon I**. The in vitro influence of 8 hormones and growth factors on the growth of 8 sarcoma cell lines. *J Cancer Res Clin Oncol.* 1998;124:155-164. IF = 1.8.

76. François C, Rimmelink M, Peteïn M, van Velthoven R, Danguy A, Wespes E, **Salmon I**, Kiss R, Decaestecker C. The chromatin pattern of cell nuclei is of prognostic value for renal cell carcinoma. *Anal Cell Pathol.* 1998;16:161-175. IF = 0.8.

77. Yeaton P, Sears RJ, Ledent T, **Salmon I**, Kiss R, Decaestecker C. Discrimination between chronic pancreatitis and pancreatic adenocarcinoma using artificial intelligence algorithms based on image cytometry generated variables. *Cytometry* 1998;32:309-316. IF = 2.6.

78. Decaestecker C, Camby I, Gordower L, Dewitte O, Cras P, Martin JJ, Pasteels JL, Van Ham P, Brotchi J, Kiss R, **Salmon I**. Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy. *J Neuropathol Exp Neurol.* 1998;57:791-802. IF = 5.6.

79. Gordower L, Decaestecker C, Lopes MB, Camby I, Nagy N, François C, Cras P, Martin JJ, Brotchi J, Kiss R, **Salmon I**. Determination of the growth fraction and cell density to evaluate the potential growth of human oligodendroglial and astrocytic tumors. *J Cancer Res Clin Oncol.* 1998;124:427-434. IF = 1.8.

80. Danguy A, Decaestecker C, Genten F, **Salmon I**, Kiss R. Applications of lectins and neoglycoconjugates in histology and pathology. *Acta Anat.* 1998;161:206-218. IF = 2.4.

81. De Hauwer C, Camby I, Darro F, Migeotte I, Decaestecker C, Verbeek C, Danguy A, Pasteels JL, Brotchi J, **Salmon I**, Van Ham P, Kiss R. Gastrin inhibits cell motility in human glioblastoma cell lines. *J Neurobiol.* 1998;37:373-382. IF = 3.5.

82. Yeaton P, Frierson HF Jr, Hittelet A, Duckworth C, DePrez C, Bourgeois N, **Salmon I**, Jones RS, Kiss R, Decaestecker C. Use of image cytometry to classify biliary and ampullary adenocarcinomas. *Anal Quant Cytol Histol.* 1998;20:509-516. IF = 0.9.

83. Camby I, Rummelink M, Nagy N, Rombaut K, Kiss R, **Salmon I**. Neuropathological consultation by means of telepathology : a clinical tool for imposing diagnosis of rare and difficult cases. *Adv Clin Path.* 1998;2:152-153. IF = /.

84. Choufani G, Saussez S, Detemmerman D, **Salmon I**, Tainmont J, Louryan S, Rummelink M, Hassid S. Yolk sac tumor of the ear in a child. *Am J Otol.* 1998;19:298-300. IF = 1.2

1999

85. Camby I, Nagy N, Lopes MB, Schäfer BW, Maurage CA, Ruchoux MM, Murmann P, Pochet R, Heizmann CW, Brotchi J, **Salmon I**, Kiss R, Decaestecker C. Supratentorial Pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins. *Brain Pathol.* 1999;9:825-843. IF = 6.4.

86. François C, Decaestecker C, De Lathouwer O, Moreno C, Peltier A, Roumeguere T, Danguy A, Pasteels JL, Wespes E, **Salmon I**, van Velthoven R, Kiss R. Improving the prognostic value of histopathological grading and clinical staging in renal cell carcinoma by means of computer-assisted microscopy. *J Pathol.* 1999;187:313-320. IF = 4.1.

87. Schwarz G Jr, Rummelink M, Decaestecker C, Gielen I, Budel V, Burchert M, Darro F, Danguy A, Gabius HJ, **Salmon I**, Kiss R. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign versus malignant uterine smooth muscle tumors. *Am J Clin Pathol.* 1999;111:623-631. IF = 2.9.

88. Steinfeld S, Penaloza A, Ribai P, Decaestecker C, Danguy A, Gabius HJ, **Salmon I**, Appelboom T, Kiss R. D-mannose and N-acetylglucosamine moieties and their respective binding sites in salivary glands of Sjögren's syndrome. *J Rheumatol.* 1999;26:833-841. IF = 2.9.

89. Nagy N, Camby I, Decaestecker C, Chaboteaux C, Gras T, Darro F, Rocmans P, Kiss R, **Salmon I**. Influence of L-triiodothyronine, L-thyroxine, estradiol-17beta, luteinizing hormone-releasing hormone, epidermal growth factor and gastrin on the cell proliferation of 35 benign and 13 malignant human thyroid tumors in organ cultures. *J Cancer Res Clin Oncol.* 1999;125:361-368. IF = 1.8.

90. François C, van Velthoven R, De Lathouwer O, Moreno C, Peltier A, Kaltner H, **Salmon I**, Gabius HJ, Danguy A, Decaestecker C, Kiss R. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinoma. *Am J Clin Pathol.* 1999;112:194-203. IF = 2.9.

91. Rummelink M, Darro F, Decaestecker C, De Decker R, Bovin NV, Gebhart M, Kaltner H, Gabius HJ, Kiss R, **Salmon I**, Danguy A. In vitro influence of lectins and neoglycoconjugates on the growth of 3 sarcoma cell lines. *J Cancer Res Clin Oncol.* 1999;125:275-285. IF = 1.8.

92. Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M, Danguy A, Gabius H, **Salmon I**, Kiss R, Camby I. Galectin-3 and galectin-3-binding-site expression in human adult astrocytic tumors and related angiogenesis. *Neuropathol Appl Neurobiol.* 1999;25:319-330. IF = 2.5.

93. Bronckart Y, Nagy N, Decaestecker C, Bouckaert Y, Rimmelink M, Gielen I, Hittelet A, Darro F, Pector JC, Yeaton P, Danguy A, Kiss R, **Salmon I**. Grading dysplasia in colorectal adenomas by means of the quantitative binding pattern determination of *Arachis hypogaea*, *Dolichos biflorus*, *Amaranthus caudatus*, *Maaackia amurensis* and *Sambucus nigra* agglutinins. *Hum Pathol.* 1999;30:1178-1191. IF = 2.9.
94. Debeir O, Decaestecker C, Pasteels JL, **Salmon I**, Kiss R, Van Ham P. Computer-assisted analysis of epiluminescence microscopy images of pigmented skin lesions. *Cytometry* 1999;37:255-266. IF = 2.6.
95. Penaloza A, Decaestecker C, Ribai P, Nagy N, **Salmon I**, Appelboom T, Danguy A, Kiss R, Steinfeld S. Sialic acid residues in the labial salivary glands from Sjögren's syndrome. *Clin Exp Rheumatol.* 1999;17:713-717. IF = 1.6.
96. Choufani G, Mahillon V, Decaestecker C, Lequeux T, Danguy A, **Salmon I**, Gabius HJ, Hassid S, Kiss R. The determination of the levels of expression of sarcolectin and calyculin and of the percentages of apoptotic, but not of proliferating cells enables recurrent from non-recurrent cholesteatomas to be identified. *Laryngoscope* 1999;109:1825-1831. IF = 1.5.
97. Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, Danguy A, Louryan S, **Salmon I**, Gabius HJ, Kiss R, Hassid S. The levels of expression of galectin-1, galectin-3 and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. *Cancer* 1999;86:2353-2363. IF = 3.6.
98. Nagy N, Decaestecker C, Kiss R, Rypens F, Van Gansbeke D, Mockel J, Rocmans P, **Salmon I**. A pilot study for identifying at risk thyroid lesions by means of a decision tree run on clinicocytological variables. *Int. J. Mol. Med.* 1999;4:299-308. IF = 1.9.
- 2000**
99. Camby I, Lefranc F, Titeca G, Neuci S, Fastrez M, Dedecken L, Schäfer BW, Brotchi J, Heizmann CW, Pochet R, **Salmon I**, Kiss R, Decaestecker C. Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumors. *Neuropathol Appl Neurobiol.* 2000;26:76-90. IF = 2.5.
100. François C, Moreno C, Teitelbaum J, Bigras G, **Salmon I**, Danguy A, Brugal G, van Velthoven R, Kiss R, Decaestecker C. Improving accuracy in the grading of renal cell carcinoma by combining quantitative description of chromatin pattern with the quantitative determination of cell kinetic parameters. *Cytometry* 2000;42:18-26. IF = 2.6.
101. Hittelet AB, Yeaton P, Decaestecker C, Rimmelink M, Nagy N, Cremer M, **Salmon I**, Kiss R, Bourgeois N. Discrimination between dysplastic and malignant epithelium of the ampulla of Vater based on quantitative image cytometric data. *Anal Quant Cytol Histol.* 2000;22: 98-106. IF = 0.9.
102. Nagy N, Decaestecker C, Dong X, Kaltner H, Schüring MP, Rocmans P, Danguy A, Gabius HJ, Kiss R, **Salmon I**. Characterization of ligands for galectins, natural galactoside-binding immunoglobulin G subfractions and sarcolectin and also of the of calyculin in thyroid lesions. *Histol Histopathol.* 2000;15:503-513. IF = 1.6.
103. Darro F, Schwarz G Jr, Pétein M, Schwarz S, Chaboteaux C, Nogaret JM, Decaestecker C, **Salmon I**, Kiss R. Characterization of steroid hormone sensitivity in human breast cancers maintained *ex vivo* under organotypical culture conditions. *J Cancer Res Clin Oncol.* 2000;126:257-262. IF = 1.8.

104. Delorge S, Saussez S, Pelc P, Devroede B, Marchant H, Burchert M, Zeng FY, Danguy A, **Salmon I**, Gabius HJ, Kiss R, Hassid S. Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. *Otolaryngol Head Neck Surg.* 2000;122:834-841. IF = 1.0.
105. Hassid S, Choufani G, Decaestecker C, Delbrouck C, Dawance S, Pelc P, Nagy N, Kaltner H, **Salmon I**, Danguy A, Gabius HJ, Kiss R. Glychohistochemical characteristics of nasal polyps from patients with and without cystic fibrosis. *Arch Otolaryngol Head Neck Surg.* 2000;126:769-776. IF = 1.5.
106. Hoyaux D, Decaestecker C, Heizmann CW, Vogl T, Schäfer BW, **Salmon I**, Kiss R, Pochet R. S100 proteins in corpora amylacea from normal human brain. *Brain Res.* 2000;867:280-288. IF = 2.5.
107. Deleu S, Allory Y, Radulescu A, Pirson I, Carrasco N, Corvilain B, **Salmon I**, Franc B, Dumont JE, Van Sande J, Maenhaut C. Characterization of autonomous thyroid adenoma : metabolism, gene expression, and pathology. *Thyroid.* 2000;10:131-140. IF = 2.0.
108. Van Laethem JL, Peny MO, **Salmon I**, Cremer M, Devière J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. *GUT.* 2000;46:574-577. IF = 5.4.
109. Kinnaert P, **Salmon I**, Decoster-Gervy C, Vienne A, De Pauw L, Hooghe L, Tielemans C. Long-term results of subcutaneous parathyroid grafts in uremic patients. *Arch Surg.* 2000;135:186-190. IF = 2.6.
110. Rummelinck M, Lopes MB, Nagy N, Rorive S, Rombaut K, Decaestecker C, Kiss R, **Salmon I**. How could static telepathology improve diagnosis in neuropathology., *Anal. Cell Pathol.* 2000;21:177-182. IF = 0.8.
111. De Witte O, Lefranc F, Levivier M, **Salmon I**, Brotchi J, Goldman S. FDG-PET as a prognostic factor in high-grade astrocytoma. *J Neurooncol.* 2000;49:157-63. IF = 1.6.
112. Kinnaert P, Nagy N, Decoster-Gervy C, De Pauw L, **Salmon I**, Vereerstraeten P. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. *World J Surg.* 2000;24:1391-5. IF = 2.0.
113. Massager N, David P, Goldman S, Pirotte B, Wikler D, **Salmon I**, Nagy N, Brotchi J, Levivier M. Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions : diagnostic yield in a series of 30 patients, *J. Neurosurg.* 2000;93:951-7. IF = 2.9.

2001

114. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, **Salmon I**, Gabius HJ, Kiss R. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. *Brain Pathol* 2001;11:12-26. IF = 8.6.
115. Camby I, Decaestecker C, Gordower L, DeDecker R, Kacem Y, Lemmers A, Siebert HC, Bovin NV, Wesseling P, Danguy A, **Salmon I**, Gabius HJ, Kiss R. Distinct differences in binding capacity to saccharide epitopes in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas. *J Neuropathol Exp Neurol* 2001;60:75-84. IF = 5.3.

116. Gabius HJ, Darro F, Rimmelin M, André S, Kopitz J, Danguy A, Gabius S, **Salmon I**, Kiss R. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. *Cancer Invest* 2001;19:114-26. IF = 1.6.
117. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S, Maurage CA, Kaltner H, Ruchoux MM, Danguy A, Gabius HJ, **Salmon I**, Kiss R, Camby I. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. *GLIA* 2001;33:241-55. IF = 4.2.
118. Bronckart Y, Decaestecker C, Nagy N, Harper L, Schäfer BW, **Salmon I**, Pochet R, Kiss R, Heizman CW. Development and progression of malignancy in human colon tissues are correlated with expression of specific Ca²⁺-binding S100 proteins. *Histol Histopathol* 2001;16:707-712. IF = 1.8.
119. Simon P, Decaestecker C, Choufani G, Delbrouck C, Danguy A, **Salmon I**, Zick Y, Kaltner H, Hassid S, Gabius HJ, Kiss R, Darro F. The levels of retinoid RARbeta receptors correlate with galectin-1, -3 and -8 expression in human cholesteatomas. *Hear Res* 2001;156: 1-9. IF = 1.6.
120. Sheikholeslam-Zadeh R, Decaestecker C, Delbrouck C, Danguy A, **Salmon I**, Zick Y, Kaltner H, Hassid S, Gabius HJ, Kiss R, Choufani G. The level of galectin-3 expression, but not of galectin-1 and -8, correlates with apoptosis in human cholesteatomas. *Laryngoscope* 2001;111:1042-47. IF = 1.4.
121. Nagy N, Brenner C, Markadiou N, Chaboteaux C, Camby I, Schäfer BW, Pochet R, Heizmann CW, **Salmon I**, Kiss R, Decaestecker C. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. *Lab Invest* 2001;81:599-612. IF = 3.9.
122. Berthe JV, Rimmelin M, Werry J, **Salmon I**, Kiss R, Decaestecker C. The contribution of image cytometry to the characterization of clinical subgroups of lipomas. *Int. J. Oncol.* 2001;18:1315-1321. IF = 2.3.
123. Steinfeld SD, Demols P, **Salmon I**, Kiss R, Appelboom T. Infliximab in patient with primary Sjögren's syndrome : A pilot study. *Arthritis Rheum.* 2001;44:2371-2375. IF = 7.4.
124. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, Dedeker R, Micik S, Brotchi J, Decaestecker C, **Salmon I**, Kiss R, Camby I. Molecular characterization of cell-substratum attachments in human glial tumors relates to prognostic features. *GLIA* 2001;36:375-390. IF = 4.2.
125. Tannouri F, Divano L, Caucheteur V, Hacourt A, Pirotte B, **Salmon I**, Balériaux D. Cavernous haemangioma in the cavernous sinus : case report and review of the literature. *Neuroradiology.* 2001;43:317-20. IF = 1.1.
126. Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, Goren R, Zich Y, Petein M, **Salmon I**, Gabius HJ, Kiss R. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. *Histol Histopathol.* 2001;16:861-8. IF = 1.8.
127. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, **Salmon I**, Brotchi J, Goldman S. Positron emission tomography with injection of methionine as a prognostic factor in glioma. *J Neurosurg.* 2001;95:746-50. IF = 2.7.

2002

128. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, **Salmon IJ**, Deschodt-

- Lanckman MM, Vanherweghem JL. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. *J Am Soc Nephrol*. 2002;13:431-6. IF = 6.4.
129. Buelens C, Bartholomé EJ, Amraoui Z, Boutriaux M, **Salmon I**, Thielemans K, Willems F, Goldman M. Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. *Blood*. 2002;99:993-8. IF = 9.6.
130. Nagy N, Hoyaux D, Gielen I, Schäfer BW, Pochet R, Heizmann CW, Kiss R, **Salmon I**, Decaestecker C. The Ca²⁺-binding S100A2 protein is differentially expressed in epithelial tissue of glandular or squamous origin. *Histol. Histopathol*. 2002;17:123-130. IF = 1.9.
131. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, **Salmon I**, Danguy A, Kiss R, Gabius HJ. Galectin-8 expression decreases in cancer as compared to normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration. *Gut* 2002;50:392-401. IF = 6.3.
132. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, **Salmon I**. Evaluation of the efficiency of chemotherapy in In Vivo orthopic models of human glioma cells with and without 1p19q and in C6 rat orthopic allografts serving for the evaluation of surgery combined with chemotherapy. *Cancer* 2002;95:641-655. IF = 3.9.
133. Surquin M, Le Moine A, Flamand V, Nagy N, Rombaut K, Demoor FX, Stordeur P, **Salmon I**, Guéry JC, Goldman M, Abramowicz D. Skin graft rejection elicited by beta2-Microglobulin as a minor transplantation antigen involves multiple effector pathways : role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates. *J Immunol* 2002;169:500-506. IF = 7.0.
134. Lefranc F, Golzarian J, Chevalier C, DeWitte O, Pochet R, Heizman C, Decaestecker C, Brotchi J, **Salmon I**, Kiss R. Expression of members of the calcium-binding S-100 protein family in a rat model of cerebral basilar artery vasospasm. *J Neurosurg* 2002;97:408-415. IF = 2.6.
135. Willermain F, Caspers-Velu L, Nowak B, Stordeur P, Mosselmans R, **Salmon I**, Velu T, Bruyns C. Retinal pigment epithelial cells phagocytosis of T lymphocytes: possible implication in the immune privilege of the eye. *Br J Ophthalmol* 2002;86:1417-1421. IF = 1.8.
136. Szeifert GT, Massager N, DeVriendt D, David P, De Smedt F, Rorive S, **Salmon I**, Brotchi J, Levivier M. Observations of intracranial neoplasms treated with gamma knife radiosurgery *J Neurosurg*. 2002;97:623-6. IF = 2.6.
137. Rorive S, Eddafali B, Fernandez S, Decaestecker C, André S, Kaltner H, Kuwabara I, Liu FT, Gabius HJ, Kiss R, **Salmon I**. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors : diagnostic and biological implications. *Modern Pathol* 2002;15(12):1294-1301. IF = 3.8.
138. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, **Salmon I**, Gabius HJ, Kiss R. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton an levels of expression of small GTPases. *J Neur Exp Neur* 2002;61:585-596. IF = 4.9.
139. Lefranc F, Camby I, Belot N, Bruyneel E, Chaboteaux C, Brotchi J, Mareel M, **Salmon I**, Kiss R. Gastrin significantly modifies the migratory abilities of experimental glioma cells. *Lab Invest*. 2002;82:1241-52. IF = 4.0.

2003

140. Nagy N, Legendre H, Engels O, André S, Kaltner H, Wasano K, Zick Y, Pector JC, Decaestecker C, Gabius HJ, **Salmon I**, Kiss R. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. *Cancer*. 2003;97:1849-58.. IF = 4.0.
141. Lefranc F, Chevalier C, Vinchon M, Dhellemmes P, Schüring MP, Kaltner H, Brotchi J, Ruchoux MM, Gabius HJ, **Salmon I**, Kiss R. Characterization of the levels of expression of retinoic acid receptors, galectin-3, macrophage migration inhibiting factor, and p53 in 51 adamantinomatous craniopharyngiomas. *J Neurosurg* 2003;98:145-153. IF = 2.3.
142. Hittélet A, Legendre H, Nagy N, Bronckart Y, Pector JC, **Salmon I**, Yeaton P, Gabius HJ, Kiss R, Camby I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. *Int J Cancer* 2003;103:370-379. IF = 4.4.
143. Buonocore S, Paulart F, Le Moine A, Braun M, **Salmon I**, Van Meirvenne S, Thielemans K, Goldman M, Flamand V. Dendritic cell overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. *Blood* 2003;101:1469-1476. IF = 10.
144. Rondelet B, Kerbaul F, Motte S, van Beneden R, Rimmelink M, Brimioulle S, McEntee K, Wauthy P, **Salmon I**, Ketelslegers JM, Naeije R. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. *Circulation* 2003;107:1329-1335. IF = 11.2.
145. Pelc P, Vanmuylder N, Lefranc F, Heizmann CW, Hassid S, **Salmon I**, Kiss R, Louryan S, Decaestecker C. Differential expression of S100 calcium-binding proteins in epidermoid cysts, branchial cysts, craniopharyngiomas and cholesteatomas. *Histopathology* 2003;42:387-394. IF = 2.9.
146. Lefranc F, Sadeghi N, Metens T, Brotchi J, **Salmon I**, Kiss R. Characterization of gastrin-induced cytostatic effect on cell proliferation in experimental malignant gliomas. *Neurosurgery* 2003;52:881-891. IF = 2.3.
147. Debelle F, Nortier J, Arlt VM, De Prez E, Vienne A, **Salmon I**, Phillips DH, Deschodt-Lanckman M, Vanherweghem JL. Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. *Arch Toxicol* 2003;77:218-226. IF = 1.6.
148. Sadeghi N, Camby I, Goldman S, Gabius HJ, Balériaux D, **Salmon I**, Decaesteckere C, Kiss R, Metens T. Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas : preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. *AJR Am J Roentgenol*. 2003;181:235-41. IF = 2.5.
149. Legendre H, Decaestecker C, Nagy N, Hendlisz A, Schüring MP, **Salmon I**, Gabius HJ, Pector JC, Kiss R. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. *Mod Pathol* 2003;16:491-504. IF = 3.3.
150. Lefranc F, Chaboteaux C, Belot N, Brotchi J, **Salmon I**, Kiss R. Determination of RNA expression for cholecystokinin/gastrin receptors (CCKA, CCKB and CCKC) in human tumors of the central and peripheral nervous system. *Int J Oncol* 2003;22:213-9. IF = 2.5.
151. Coppens AG, **Salmon I**, Heizmann CW, Kiss R, Poncelet L. Postnatal maturation of the dog stria vascularis – an immunohistochemical study. *Anat Rec A Discov Mol Cell Evol Biol*. 2003;270:82-92. IF = 1.9.

152. Pirotte B, Goldman S, Salzberg S, Wikler D, David P, Vandesteene A, Van Bogaert P, **Salmon I**, Brotchi J, Levivier M. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children : experience in 9 cases. *Pediatr Neurosurg* 2003;38 :146-55. IF = 1.0.

153. Vandermissen B, **Salmon I**, Hildebrand J. Recurrent nonhemorrhagic mass lesion due to cerebral amyloid antiopathy. *J Neurol* 2003;250:239-40. IF = 2.8.

154. Dimopoulos G, Piagnerelli M, Berré J, Eddafali B, **Salmon I**, Vincent JL. Disseminated aspergillosis in intensive care unit patients : an autopsy study. *J Chemother* 2003;15:71-5. IF = 1.1.

155. Hittelet A, Camby I, Nagy N, Legendre H, Bronckart Y, Decaestecker C, Kaltner H, Nifant'ev NE, Bovin NV, Pector JC, **Salmon I**, Gabius HJ, Kiss R, Yeaton P. Binding sites for Lewis antigens are expressed by human colon cancer cells and negatively affect their migration. *Lab Invest* 2003;83:777-87. IF = 4.4.

156. Szeifert GT, **Salmon I**, Balériaux D, Brotchi J, Levivier M. Immunohistochemical analysis of a cerebral arteriovenous malformation obliterated by radiosurgery and presenting with re-bleeding. Case report. *Neurol Res* 2003;25:718-21. IF = 1.0.

157. Lubansu A, Ruchoux MM, Brotchi J, **Salmon I**, Kiss R, Lefranc F. Cathepsin B, D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression. *Histopathology* 2003;43:563-572. IF = 2.9.

158. Saal I, Gustin A, Rombaut K, Pelaez P, Rorive S, Rummelink M, **Salmon I**. Laser-assisted microdissection applied to frozen surgical pathologic specimens – methodological aspects on RT-PCR. *J Exp Ther Oncol* 2003;3:1-11. IF = /.

2004

159. Maurer P, Rorive S, de Kerchove d'Exaerde A, Schiffmann SN, **Salmon I**, de Launoit Y. The Ets transcription factor Fev is specifically expressed in the human central serotonergic neurons. *Neurosciences Letters* 2004;357:215-218. IF = 2.0.

160. Vray B, Camby I, Vercruysse V, Mijatovic T, Bovin NV, Ricciardi-Castagnoli P, Kaltner H, **Salmon I**, Gabius HJ, Kiss R. Up-regulation of galectin-3 and its ligands by *Trypanosoma cruzi* infection with modulation of adhesion and migration of murine dendritic cells. *Glycobiology* 2004;14:647-657. IF = 4.1.

161. Beuneu C, Vosters O, Movahedi B, Rummelink M, **Salmon I**, Pipeleers D, Pradier O, Goldman M, Verhasselt V. Human pancreatic duct cells exert tissue factor-dependent procoagulant activity. *Diabetes* 2004;53:1407-1411. IF = 8.8.

162. Dimopoulos G, Piagnerelli M, Berré J, **Salmon I**, Vincent JL. Post mortem examination in the intensive care unit : still useful ? *Intensive Care Medicine* 2004;30:2080-5. IF = /.

163. Mathieu A, Rummelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, **Salmon I**. Development of a chemoresistant orthotopic human non-small cell lung carcinoma model in nude mice: analyses of tumor heterogeneity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu,

and GST-pi. *Cancer* 2004;101:1908-1918. IF = 4.4.

164. Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, Hubloue I, Rimmelink M, Brimioulle S, **Salmon I**, Ketelslegers JM, Naeije R. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets. Effects of Sildenafil therapy. *Circulation* 2004;110:2220-2225. IF = 12.6.

165. Aguemon B, Struelens M, Deviere J, Denis O, Golstein P, Nagy N, **Salmon I**. Evaluation of stool antigen detection for diagnosis of *Helicobacter pylori* infection in adults. *Acta Clin Belg* 2004;59:246-50. IF = 0.4.

166. Lefranc F, Mijatovic T, Mathieu V, Rorive S, Decaestecker C, Debeir O, Brotchi J, Van Ham P, **Salmon I**, Kiss R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. *Clin Cancer Res* 2004;10:8250-65. IF = 5.6.

167. Debelle FD, Nortier JL, Husson CP, De Prez EG, Vienne AR, Rombaut K, **Salmon IJ**, Deschodt-Lanckman MM, Vanherweghem JL. The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids. *Kidney Int* 2004;66:1815-25. IF = 4.8.

168. Hancq S, **Salmon I**, Brotchi J, Gabius HJ, Heizmann CW, Kiss R, Decaestecker C. Detection of S100B, S100A6 and galectin-3 ligands in meningiomas as markers of aggressiveness. *Int J Oncol* 2004;25:1233-40. IF = 3.1.

169. Coppens AG, **Salmon I**, Heizmann CW, Poncelet L. Dark-cell areas in the dog vestibular endorgans : an immunohistochemical study. *Histol Histopathol* 2004;19:1227-35. IF = 1.9.

170. Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, **Salmon I**, Brotchi J, Levivier M. Combined used of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. *J Neurosurg* 2004;101:476-83. IF = 2.6.

171. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, **Salmon I**, Brotchi J, Levivier M. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. *J Nucl Med* 2004;45:1293-8. IF = 5.4.

172. Vosters O, Beuneu C, Nagy N, Movahedi B, Aksoy E, **Salmon I**, Pipeleers D, Goldman M, Verhasselt V. CD40 expression on human pancreatic duct cells : role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. *Diabetologia* 2004;47:660-8. IF = 5.6.

173. Loi P, Paulart F, Pajak B, Nagy N, **Salmon I**, Moser M, Goldman M, Flamand V. The fate of dendritic cells in a mouse model of liver ischemia/reperfusion injury. *Transplant Proc* 2004;36:1275-9. IF = 0.5.

174. Hancq S, **Salmon I**, Brotchi J, De Witte O, Gabius HJ, Heizmann CW, Kiss R, Decaestecker C. S100A5: a marker of recurrence in WHO grade I meningiomas. *Neuropathol Appl Neurobiol.* 2004;30:178-87. IF = 3.4

2005

175. Rimmelink M, Mijatovic T, Gustin A, Mathieu A, Rombaut K, Kiss R, **Salmon I**, Decaestecker C. Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. *Int J Oncol* 2005;26:247-258. IF = 2.7.

176. Szeifert GT, **Salmon I**, Rorive S, Massager N, Devriendt D, Simon S, Brotchi J, Levivier M. Does gamma knife surgery stimulate cellular immune response to metastatic brain tumors? A

histopathological and immunohistochemical study. *J Neurosurg* 2005;102:180-4. IF = 2.4.

177. Lefranc F, Mijatovic T, Decaestecker C, Kaltner H, Andre S, Brotchi J, **Salmon I**, Gabius HJ, Kiss R. Monitoring the expression profiles of integrins and adhesion/growth-regulatory galectins in adamantinomatous craniopharyngiomas : their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis. *Neurosurgery* 2005;56:763-776. IF = 2.6.

178. Mathieu A, Saal I, Vuckovic A, Ransy V, Vereerstraten P, Kaltner H, Gabius HJ, Kiss R, Decaestecker C, **Salmon I**, Rummelink M. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. *Modern Pathol* 2005;18:1264-1274. IF = 3.4.

179. D'Haene N, Maris C, Sandras F, Dehou MF, Rummelink M, Decaestecker C, **Salmon I**. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and Non-Hodgkin's and Hodgkin's lymphomas. *Int J Immunopath Pharmacol* 2005;18:431-443. IF = 3.4.

180. Surquin M, Le Moine A, Flamand V, Rombaut K, Demoor FX, **Salmon I**, Goldman M, Abramowicz D. IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts. *Transplantation* 2005;80:1485-1492. IF = 3.9.

181. de Lavarelle A, Prigogine C, Paulart F, Nagy N, Habran C, Haddou NO, Le Moine A, **Salmon I**, Goldman M, Flamand V. Regulatory role of host CD8+ T lymphocytes in experimental graft-versus-host disease across a single major histocompatibility complex class II incompatibility. *Transplantation* 2005;80:1293-1299. IF = 3.9.

182. Agumon B, Struelens M, Devière J, Denis O, Golstein P, **Salmon I**, Nagy N. Primary antibiotic resistance and effectiveness of *Helicobacter pylori* triple therapy in ulcero-inflammatory pathologies of the upper digestive tract. *Acta Gastroenterol Belg* 2005;68:287-293. IF = 0.8.

183. Saal I, Nagy N, Lensch M, Lohr M, Manning JC, Decaestecker C, André S, Kiss R, **Salmon I**, Gabius HJ. Human galectin-2: expression profiling by RT-PCR/immunohistochemistry and its introduction as a histochemical tool for ligand localization. *Histol Histopathol* 2005;20:1191-1208. IF = 2.0.

184. Mathieu A, Chamlou R, Le Moine F, Maris C, Van de Stadt J, **Salmon I**. Tailgut cyst associated with a carcinoid tumor : case report and review of the literature. *Histol Histopathol* 2004;20:1065-1069. IF = 2.0.

185. Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Rummelink M, Brimiouille S, **Salmon I**, Naeije R. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. *Am J Physiol Heart Circ Physiol* 2005;289:H23 19-24. IF = 3.6.

2006

186. Graça J, Gültasli N, D'Haene N, Brotchi J, **Salmon I**, Balériaux D. Cystic extramedullary ependymoma. *Am J Neuroradiol* 2006;27:818-821. IF = 2.3.

187. Rorive S, Maris C, Debeir O, Sandras F, Vidaud M, Bièche I, **Salmon I**, Decaestecker C. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. *J Neuropathol Exp Neurol* 2006;65:794-

807. IF = 4.4.

188. Sadeghi N, **Salmon I**, Tang BN, Denolin V, Levivier M, Wikler D, Rorive S, Balériaux D, Metens T, Goldman S. Correlation between dynamic susceptibility contrast perfusion MRI and Methionine metabolism in brain gliomas : preliminary results. *J Magn Reson Imaging* 2006;24:989-994. IF = 2.6.

2007

189. Lévy P, Ripoche H, Laurendeau I, Lazar V, Ortonne N, Parfait B, Leroy K, Wechsler J, **Salmon I**, Wolkenstein P, Dessen P, Vidaud M, Vidaud D, Bièche I. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. *Clin Cancer Res* 2007;15:398-704. IF = 6.2.

190. Maris C, Martin B, Creteur J, Rummelink M, Piagnerelli M, **Salmon I**, Vincent JL, Demetter P. Comparison of clinical and post-mortem findings in intensive care unit patients. *Virchows Arch* 2007;450:329-33. IF = 2.0.

191. Rondelet B, Kerbaul F, Vivian GF, Hubloue I, Huez S, Fesler P, Rummelink M, Brimiouille S, **Salmon I**, Naeije R. Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension. *Pediatr Res* 2007;61:284-8. IF = 2.8.

192. Szeifert GT, Kondziolka D, Lunsford LD, Nyáry I, Hanzély Z, **Salmon I**, Levivier M. Introduction : the contribution of pathology to radiosurgery. *Prog Neurol Surg* 2007;20:1-15. IF = /.

193. Szeifert GT, Kondziolka D, Atteberry DS, **Salmon I**, Rorive S, Levivier M, Lunsford LD. Radiosurgical pathology of brain tumors : metastases, schwannomas, meningiomas, astrocytomas, hemangioblastomas. *Prog Neurol Surg* 2007;20:91-105. IF = /.

194. Szeifert GT, **Salmon I**, Lorenzoni J, Massager N, Levivier M. Pathological findings following trigeminal neuralgia radiosurgery. *Prog Neurol Surg* 2007;20:244-8. IF = /.

195. Sadeghi N, **Salmon I**, Decaestecker C, Levivier M, Metens T, Wikler D, Denolin V, Rorive S, Massager N, Baleriaux D, Goldman S. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. *Am J Neuroradiol* 2007;28:455-61. IF = 2.3.

196. Taccone FS, **Salmon I**, Marechal R, Blecic SA. Paraneoplastic vasculitis of central nervous system presenting as recurrent cryptogenic stroke. *Int J Clin Oncol* 2007;12:155-9. IF = /.

197. Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, **Salmon I**, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C. Trisomy 19 ependymoma, a newly recognized genético-histological association, including clear cell ependymoma. *Mol Cancer* 2007;6:47. IF = 3.7.

2008

198. Sadeghi N, D'Haene N, Decaestecker C, Levivier M, Metens T, Maris C, Wikler D, Baleriaux D, **Salmon I**, Goldman S. Apparent diffusion coefficient and cerebral blood volume in brain gliomas : relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. *Am J Neuroradiol* 2008;29:476-482. IF = 2.7.

199. D'Haene N, Catteau X, Maris C, Martin B, **Salmon I**, Decaestecker C. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central

- nervous system lymphomas. *Br J Haematol* 2008;140:402-410. IF = 4.5.
200. Pozdzik AA, **Salmon IJ**, Debelle FD, Decaestecker C, Van den Branden C, Verbeelen D, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. *Kidney Int* 2008;73:595-607. IF = 6.4.
201. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, Decaestecker C, **Salmon I**, Abramowicz D, Vanherweghem JL, Nortier J. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy : a case series with 15-year follow-up. *Am J Kidney Dis* 2008;51:471-477. IF = 4.8.
202. Chamekh M, Phalipon A, Quertainmont R, **Salmon I**, Sansonetti P, Allaoui A. Delivery of biologically active anti-inflammatory Cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion apparatus. *J Immunol* 2008;180:4292-4298. IF = 6.0.
203. Demetter P, Nagy N, Martin B, Mathieu A, Dumont P, Decaestecker C, **Salmon I**. The galectin family and digestive disease. *J Pathol* 2008;215:1-12. IF = 5.1.
204. Maris C, Rorive S, Sandras F, D'Haene N, Sadeghi N, Bièche I, Vidaud M, Decaestecker C, **Salmon I**. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas. *Neuropathol Appl Neurobiol* 2008;34:316-329. IF = 3.7.
205. Pozdzik AA, **Salmon IJ**, Husson CP, Decaestecker C, Rogier E, Bourgeade MF, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. *Nephrol Dial Transplant* 2008;23:2480-2491. IF = 3.6.
206. Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, **Salmon I**. Expression of galectin-3 in the tumor immune response in colon cancer. *Laboratory Investigation* 2008;88:896-906. IF = 4.6.
207. Rorive S, Berton A, D'haene N, Takacs CN, Debeir O, Decaestecker C, **Salmon I**. Matrix Metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. *GLIA* 2008;56:1679-1690. IF = 5.6.
208. Mathieu A, Nagy N, Decaestecker C, Ferdinande L, Vandenbroucke K, Rottiers P, Cuvelier CA, **Salmon I**, Demetter P. Expression of galectins-1, -3 and -4 varies with strain and type experimental colitis in mice. *Int J Exp Pathol* 2008;89:438-446. IF = 2.2.
- 2009**
209. de Hemptinne Q, Rimmelink M, Brimiouille S, **Salmon I**, Vincent JL. ARDS : a clinicopathological confrontation. *Chest* 2009;135:944-949. IF = 6.3.
210. D'Haene N, Coen N, Neugroschl C, Balériaux D, **Salmon I**. Leptomeningeal dissemination of low-grade intramedullary gliomas : about one case and review. *Clin Neurol Neurosurg* 2009;111:390-394. IF = 1.3.
211. Massager N, Maris C, Nissim O, Devriendt D, **Salmon I**, Levivier M. Experimental analysis of radiation dose distribution in radiosurgery: I. Dose hot spot inside target volume. *Stereotact Funct Neurosurg* 2009;87:82-87. IF = 1.4.
212. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, **Salmon I**, Devière J, Van Laethem JL. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in

resected pancreatic adenocarcinome. Clin Cancer Res 2009;15:2913-2919. IF = 6.7.

213. Massager N, Maris C, Nissim O, Devriendt D, **Salmon I**, Levivier M. Experimental analysis of radiation dose distribution in radiosurgery. II. Dose fall-off outside the target volume. Stereotact Funct Neurosurg 2009;87:137-142. IF = 1.4.

214. Devosse T, Guillabert A, D'Haene N, Berton A, De Nadai P, Noel S, Brait M, Franssen JD, Sozzani S, **Salmon I**, Parmentier M. Formyl peptide receptorlike 2 is expressed and functional in plasmacytoid dendritic cells, tissue-specific macrophage subpopulations and eosinophils. J Immunol 2009;182:4974-4984. IF = 5.6.

215. Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Devière J, **Salmon I**, Van Laethem JL. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009;100:1444-1451. IF = 4.3.

216. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, **Salmon I**, Szijan I. Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest 2009;27:691-698. IF = 2.1.

217. Palm T, Figarella-Branger D, Chapon F, Lacroix C, Gray F, Scaravilli F, Ellison DW, **Salmon I**, Vikkula M, Godfraind C. Expression profiling of épendymomes unravels localization and tumor grade-specific tumorigenesis. Cancer 2009;115: 3955-3968. IF = 5.4.

218. Decaestecker C, Lopez XM, D'Haene N, Roland I, Guendouz S, Duponchelle C, Berton A, Debeir O, **Salmon I**. Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics 2009;9:4478-4494. IF = 4.4.

219. Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, **Salmon I**, Braun MY. Reviving function in CD4+ T cells adapted to persistent systemic antigen. J Immunol 2009;183:4284-4291. IF = 5.6.

2010

220. Mathieu A, Weynand B, Verbeken E, Da Silva S, Decaestecker C, **Salmon I**, Demetter P. Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 2010;69:46-50. IF = 3.1.

221. Rorive S, D'Haene N, Fossion C, Delpierre I, Abarguia N, Avni F, Decaestecker C, **Salmon I**. Ultrasound-guided fine-needle aspiration of thyroid nodules : stratification of malignancy risk using follicular proliferation grading, clinical and ultrasonographic features. Eur J Endocrinol 2010;162:1107-15. IF=3.5.

222. Laurendeau I, Ferrer M, Garrido D, D'haene N, Ciavarelli P, Basso A, Vidaud M, Bieche I, **Salmon I**, Szijan I. Gene expression profiling of the Hedgehog signaling pathway in human meningiomas. Mol Med. 2010. [Epub ahead of print] IF = 5.0.

223. Flamez D, Roland I, Berton A, Kutlu B, Dufrane D, Beckers MC, De Waele E, Rooman I, Bouwens L, Clark A, Lonneux M, Jamar JF, Goldman S, Maréchal D, Goodman N, Gianello P, Van Huffel C, **Salmon I**, Eizirik DL. A genomic-based approach identifies FXYP domain containing ion transport regulator 2 (FXYP2)gamma as a pancreatic beta cell-specific biomarker. Diabetologia 2010;53:1372-83. IF = 6.5.

224. Pozdzik AA, Berton A, Schmeiser HH, Missoum W, Decaestecker C, **Salmon IJ**, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity? Histopathology 2010;56:449-63. IF = 3.8.

225. Rivas MN, Hazzan M, Weatherly K, Gaudray F, **Salmon I**, Braun MY. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. *J Immunol* 2010;184:6790-8. IF = 5.6.

226. Maréchal R, De Schutter J, Nagy N, Demetter P, Lemmers A, Devière J, **Salmon I**, Tejpar S, Van Laethem JL. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. *BMC Cancer*. 2010 Jun 30;10:340.

227. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, **Salmon I**, Devière J, Van Laethem JL. Deoxycytidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. *Cancer*. 2010 Nov 15;116(22):5200-6.

228. Rorive S, Lopez XM, Maris C, Trepant AL, Sauvage S, Sadeghi N, Roland I, Decaestecker C, **Salmon I**. TIMP-4 and CD63: New Prognostic Biomarkers in Human Astrocytomas. *Mod Pathol*. 2010 Oct;23(10):1418-28 IF = 4.4

2011

229. Poncelet L, **Salmon I**, Jolly S, Summers BA. Primary bilateral pontine demyelination in a cat with similarity to central pontine myelolysis. *Vet Pathol*. 2011 May;48(3):751-3. IF=1.9

230 De Tiège X, Van Bogaert P, Aeby A, **Salmon I**, Parpal H, Poppe AY, Maris C, Lanthier S. Primary angioitis of the central nervous system: neurologic deterioration despite treatment. *Pediatrics*. 2011 Apr;127(4):e1086-90. IF=5.4

231. Norrenberg S, Rorive S, Laskar P, Catteau X, Delpierre I, Avni FE, **Salmon I**. Acute transient thyroid swelling after fine needle aspiration biopsy (FNAB):rare complication of unknown origin. *Clin Endocrinol (Oxf)*. 2011 Oct.75(4):568-70. IF=3.2

232. Devosse T, Dutoit R, Migeotte I, De Nadai P, Imbault V, Communi D, **Salmon I**, Parmentier M.Processing HEBP1 by Cathepsin D Gives Rise to F2L, the Agonist of Formyl Peptide Receptor 3. *J Immunol*. 2011 Aug 1;187(3):1475-85. IF=5.8

233. Abeloos L, Maris C, **Salmon I**, Balériaux D, Sadeghi N, Lefranc F. Chondroma of the dural convexity : a case report and literature review. *Neuropathology*. 2011 Oct 24. IF=2.1

234. Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, **Salmon I**, Cuvelier CA, Demetter P. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. *Br J Cancer*. 2012 Jan 3;106(1):141-7. IF=5.0

235. Lv S, Teugels E, Sadones J, Quartier E, Huylebrouck M, DU Four S, Le Mercier M, De Witte O, **Salmon I**, Michotte A, De Grève J, Neyns B. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent Glioma. *Anticancer Res*. 2011 Dec;31(12):4457-63. IF=1.7

2012

236. Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, **Salmon I**, Cuvelier CA, Demetter P. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. *Br J Cancer*. 2012 Jan 3;106(1):141-7. IF=5.0

237. Abeloos L, Maris C, **Salmon I**, Balériaux D, Sadeghi N, Lefranc F. Chondroma of the dural convexity: a case report and literature review. *Neuropathology*. **2012** Jun;32(3):306-10. IF =2.0
238. Lopez XM, Debeir O, Maris C, Rorive S, Roland I, Saerens M, **Salmon I**, Decaetecker C. Clustering methods applied in the detection of K167 hot-spots in whole tumor slide images : An efficient way to characterize heterogeneous tissue-bases biomarkers. *Cytometry A*.2012 Sep; 81(9):765-75. IF=3.7
239. Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, **Salmon I**, Devière J, Emile JF, Van Laethem JL.. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. *Gastroenterology*. 2012 Sep; 143(3):664-674. IF= 11.6
240. Marhfour I, Lopez XM, Lefkaditis D, **Salmon I**, Allagnat F, Richardson SJ, Morgan NG, Eizirik DL. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. *Diabetologica*. 2012 Sep;55(9):2417-20. IF=6.8
241. Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Vaillant JC, André T, Closset J, **Salmon I**, Emile JF, Van Laethem JL. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. *Ann Oncol*. 2012 Sep;23(9):2327-35. IF=6.4
242. Huylebrouck M, Lv S, Duerinck J, Van Binst A, **Salmon I**, De Greve J, De Witte O, Luce S, Michotte A, D'Haens J, Neyns B. An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two belgian university hospitals. *J Oncol*. 2012:801306. IF=/

Articles in international scientific journals without lecture committee

1. **Salmon I**, Kiss R, Segers V, Carroyer JM, Levivier M, Pasteels JL, Brotchi J, Flament-Durand J: Characterization of nuclear size, ploidy, DNA histogram type, and proliferation index in 79 nerve sheath tumors. *Anticancer Res* 1992;12:2277-2284. IF = 1.3.
2. Kruczynski A, **Salmon I**, Camby I, Limouzy A, Rombaut K, Pasteels JL, Delsol G, Brotchi J, Kiss R: The characterization of nuclear DNA content, the proliferative activity and the immunohistochemical expression of GFAP, VIM, LEU-7, S-100, p53 and cathepsin D in human glioblastoma multiformes (hGBMs) versus human GBM cell lines grafted into the brains of nude mice. *Int J Oncol* 1995;6:473-481. IF = 2.1.
3. **Salmon I**, Cras P, Rummelink M, Henrion S, Pasteels JL, Brotchi J, Kiss R: Computer-assisted quantitative description of chromatin pattern and DNA ploidy level in ependymomas and choroid plexus tumours. *Int J Oncol* 1995;6:919-924. IF = 2.1.
4. Decaestecker C, Camby I, **Salmon I**, Brotchi J, Pasteels JL, Kiss R, Van Ham Ph: The combined use of the decision tree technique and the computer-assisted microscope analysis of Feulgen-stained nuclei as an aid for astrocytic tumour aggressiveness characterization. *Int J Oncol* 1995;7:183-189. IF = 2.1.
5. Decaestecker C, Rummelink M, Camby I, **Salmon I**, Goldschmidt D, Van Ham Ph, Pasteels JL, Kiss R: The combination of a decision tree technique with the computer-assisted microscope analysis of Feulgen-stained nuclei to assess aggressiveness in lipomatous and smooth muscle tumors. *Anticancer Res* 1995;15:1311-1318. IF = 1.3.

6. Danguy A, Remmelink M, Goldschmidt D, Camby I, Rombaut K, DeDecker R, Serpe M, Kiss R, **Salmon I**. Lectin histochemistry, ploidy level, and proliferative activity in rhabdomyosarcoma subtypes. *Int J Oncol*. 1996;8:383-388. IF = 2.1.
7. Camby I, **Salmon I**, Rombaut K, Pasteels JL, Kiss R, Danguy A. Influence of culture media and multidrug resistance on the Wheat Germ Agglutinin (WGA) glycochemical expression of two human glioblastoma cell lines. *Anticancer Res*. 1996;16:1719-1726. IF = 1.3.
8. Hassid S, Choufani G, El-Kattabi O, Dawance S, Decaestecker C, Brugmans M, Danguy A, Pasteels JL, **Salmon I**, Kiss R. Image cytometry characterization of ploidy level, proliferative activity and chromatin pattern in 50 nasal polyps. *Int J Oncol*. 1996;9:137-143. IF = 2.1.
9. Goldschmidt D, Decaestecker C, Berthe JV, Remmelink M, Petein M, Swift A, Pasteels JL, **Salmon I**, Kiss R. The characterization of biological features in dedifferentiated liposarcomas by means of principal components and discriminant analyses of 25 computer-generated variables from Feulgen-stained nuclei and histological slides. *Int J Oncol*. 1996;9:963-970. IF = 2.1.
10. Remmelink M, **Salmon I**, Delville JP, Goldschmidt D, Capel P, Gebhart M, Pasteels JL, Kiss R, Darro F. In vitro characterisation of soft tissue tumor chemosensitivity. *Anticancer Res*. 1997;17: 2009-2017. IF = 1.3.
11. Nagy N, Decaestecker C, Kiss R, Rypens F, Van Gansbeke D, Mockel J, Rocmans P, **Salmon I**. The use of an artificial intelligence-related algorithm to evaluate malignancy potential in thyroid nodules by means of 9 clinico-cytological variables. *Int J Mol Med*. 1999;4:299-308. IF = 1.9.
12. Oulab Ben Taib N, Nagy N, **Salmon I**, David P, Brotchi J, De Witte O. Malignant rhabdoid tumors of the central nervous system. Report of a case. *Neurochirurgie* 1999;45:237-242. IF = 0.4.
13. Szeifert G T, Vandersmissen B, Oulad Ben Taib N, Balériaux D, Rodesch G, **Salmon I**, Brotchi J, Levivier M. Recurrent hemorrhage in a radiosurgically obliterated cerebral arteriovenous malformation. *Radiosurgery* 2002;4:34-41. IF = /.
14. Szeifert G T, **Salmon I**, David P, Devriendt D, De Smedt F, Rorive S, Brotchi J, Levivier M. Tumor control and growth in a patient with two cerebral metastases treated with the Leksell Gamma Knife. *Radiosurgery* 2002;4:152-161. IF = /.
15. Szeifert GT, Kondziolka DS, Lunsford LD, Hanzély Z, Nyary I, **Salmon I**, Levivier M. What can we learn from Pathology ? From the beginnings towards radiosurgical pathology. *Radiosurgery* 2004;5:1-9. IF = /.

Articles in national scientific journals

1. **Salmon I**, Dussart M, Paulet Ph. Cirrhose biliaire primitive asymptomatique. *Acta Gastro-Enterol* 1984;47:500-505. IF 2000 =0.6.
2. Van Gansbeke D, Gillard I, **Salmon I**, Matos C, Verhest A, Struyven J. Technique et indications des ponctions cytologiques de la surrenale. *Rev Méd Brux* 1998;9:455-461. IF = /.
3. Gevenois PA, **Salmon I**, Pamart D, Van Regemorter G, Struyven J. Le cancer localisé de la prostate. L'IRM a-t-elle une place diagnostique ? *Echorevue* 1988;11:6-9. IF = /.

4. **Salmon I**, Van Gansbeke D, Rahier I, Verhest A: Ponctions à l'aiguille fine des masses surrénaliennes. *Revue Française des Laboratoires* 1989;198:73-77. IF = /.
5. Gevenois PA, Stallenberg B, Van Sinoy ML, **Salmon I**, Van Regemorter G, Struyven J. Place diagnostique de l'IRM dans le cancer localisé de la prostate. *Ann Radiol* 1989;32:163-167. IF = /.
6. Gevenois PA, Sintzoff SA Jr, Stallenberg B, **Salmon I**, Simon J, Van Regermorter G, Struyven J: Gadolinium-DOTA enhanced MR imaging of prostatic lesions. Preliminary results on 14 cases. *JBR - BTR* 1992;75:5-10. IF = /.
7. Sintzoff SA Jr, Gillard I, Van Gansbeke D, Gevenois PA, **Salmon I**, Struyven J: Ultrasound evaluation of soft tissue tumors. *JBR - BTR* 199;75:276-280. IF = /.
8. Rypens F, **Salmon I**, Tielemans C, Kinnaert P: Glande parathyroïde ectopique découverte à l'examen physique. *Néphrologie* 1994;15:299-300. IF 2000 =0.5.
9. Noterman J, Patay Z, DeWitte O, **Salmon I**, Brotchi J. Unilateral amaurosis due to sphenoid sinus osteoma with mucocele. A case report. *Neurochirurgie* 1995;41:419-423. IF 2000 =0.4.
10. **Salmon I**, Dewitte O, Rimmelink M, Pasteels JL, Brotchi J, Kiss R: Valeur diagnostique et/ou pronostique de la détermination du contenu nucléaire en acide deoxyribonucléique (ADN) dans les tumeurs du système nerveux. *Rev Med Brux* 1995;16:129-134. IF = /.
11. DeWitte O, Lefranc F, **Salmon I**, Violon P, Brotchi J. Métastases cérébrales d'origine gynécologique. *Neurochirurgie* 1996;42:216-220. IF 2000 =0.4.
12. **Salmon I**. Mise en évidence de nouveaux marqueurs diagnostiques et pronostiques des tumeurs astrocytaires humaines. *Bull Mem Acad R Med Belg.* 1998;153:199-207. IF = /.
13. Nagy N, **Salmon I**. Adénome hypophysaire et tumeurs de la selles turcique : aspect anatomopathologique. *Radiologie J. CEPUR* 1998;18/6:381-387.
14. Oulab Ben Taib N, Nagy N, **Salmon I**, David P, Brotchi J, De Witte O. Malignant rhabdoid tumors of the central nervous system. Report of a case. *Neurochirurgie* 1999;45:237-242. IF 2000 =0.4.
15. Nagy N, **Salmon I**. Tumeurs cérébrales : aspect anatomopathologique. *Radiologie J. CEPUR* 1999;19/6:237-242. IF = /.
16. Bier JC, Caroyer JM, **Salmon I**, Zegers De Beyl, D. Encephalomyelopathy associated with monoclonal gammopathy. *Rev Neurol (Paris)* 2001;57:543-6. IF = 0.7
17. Nagy N, Rimmelink M, Van Vooren J., **Salmon I**. Infections gastro-intestinales chez le patient immunocompromis. *Acta Endoscopica* 2002;32:195-210. IF = /.
18. **Salmon I**, Nagy N, Noel JC, Rimmelink M. The pathology department. *Rev Med Brux* 2002;23:17-21. IF = /.
19. Szeifert GT, **Salmon I**, Balériaux D, Brotchi J, Levivier M. Immunohistochemical analysis of a cerebral arteriovenous malformation obliterated by radiosurgery and presenting with re-bleeding. Case report. *Neurol Res* 2003;25:718-721. IF = 1.0
20. Vanmuylder N, Evrard L, Glineur R, **Salmon I**, Gashegu J, Rooze M, Louryan S. Histologic and ultrastructural features of cell death both physiological and induced by two different teratogens in branchial arches of mouse embryo. *Rev Med Brux* 2004;25:14-20. IF = /.

21. D'Haene N, Salik D, Hanset M, Salmon I. A case of von Hippel-Linday disease diagnosed at the autopsy. *Rev Med Brux.* 2010 Mar-Apr;31(2):122-6. IF=/
22. Demetter P, Maréchal R, Verset L, **Salmon I**, Bachet JB, Van Laethem JL. Molecular changes in pancreatic cancer : implications for molecular targeting therapy. *Acta Gastroenterol Belg.* 2012 Jun, 75(2): 210-4. IF=0.6

COMMUNICATIONS PUBLISHED IN PROCEEDINGS OF NATIONAL AND INTERNATIONAL CONFERENCES

Nationals

1. **Salmon I**, Verhest A: Apport de la cytoponction thyroïdienne à la décision opératoire. A.M.U.B. Colloques chirurgicaux, Charleroi, 15 décembre 1988.
2. Van Gansbeke D, **Salmon I**, Tack D, Adler M, Struyven J: Updating of abdominal cytological punctures: preliminary results. Belgian Week of Gastroenterology, Liège, mars 1989.
3. **Salmon I**: Cytologie thyroïdienne à l'aiguille fine: développements récents. Société Belge d'Endocrinologie, Bruxelles, octobre 1990.
4. Thielemans P, Decaux G, Mockel J, Rocmans P, **Salmon I**, Unger J: Elévation de l'antigène carcinoembryonnaire révélatrice d'un carcinome médullaire de la thyroïde. Société Belge de Médecine Interne. Bruxelles, mars 1991.
5. Camby I, Kiss R, **Salmon I**: The use of the DNA ploidy level as a prognostic marker in adult astrocytic tumors. Second Meeting of the Neuro-Oncology Group, Gand, juillet 1994.
6. **Salmon I**: Cytologie des nodules froids: une approche intégrée multidisciplinaire. Belgian Thyroid Club. Sixth meeting, Bruxelles, mai 1995.
7. Godfraind C, **Salmon I**: New approaches to nervous tumors diagnosis. Joint Meeting of the Belgian Society of Pathology and the Belgian Group of Neuropathologists. Bruxelles, mai 1997.
8. **Salmon I**: Classification neuropathologique des tumeurs de l'enfant. Journée Annuelle de Neurologie Pédiatrique de l'Hôpital Erasme. Bruxelles, juin 1997.
9. Sicaro A, David P, Roger T, Levivier M, **Salmon I**, Balériaux D: The use and need of stereotactic biopsy in periventricular lesions. Société Royale Belge de Radiologie. Bruges, février 1998.
10. Bronckart Y, **Salmon I**, Danguy A, Kiss R: Grading dysplasia in colorectal adenomas by means of the quantitative binding pattern determination of Arachis hypogaea, Dolichos biflorus, Amaranthus caudatus, Maackia amurensis and Sambucus nigra agglutinins. Société Belge de Biochimie, Bruxelles (UCL), 27 février 1999. *Arch Physiol Biochem* 1999;107: B4.
11. Szeifert GT, **Salmon I**, David P, Devriendt D, Desmedt F, Rorive S, Brotchi J, Levivier M: Simultaneous detection of tumor control and growth in a patient with two cerebral metastases treated with Gamma Knife radiosurgery. Société Belge de Neurochirurgie, 10 mars 2001.
12. Balériaux D, Carvalho S, **Salmon I**, Brotchi J. Intra- or extra-medullary Th9-Th11 lesion : what is your diagnosis ? ». Société Royale Belge de Radiologie, Bruxelles (Saint-Elisabeth des Cliniques de l'Europe), 29 avril 2002.

13. De Tiège X, Goldman S, Lossius A, Lassoued H, Fricxs C, Detemmerman D, Pirotte B, Massager N, **Salmon I**, Van Bogaert P. Isolated angitis of the CNS as a cause of « vanishing tumor ». Société européenne de Neurologie Pédiatrique.

French language

14. **Salmon I**, Verhest A: Deux cas inhabituels de ponction de masse surrenalienne. Soc Franç Cytol Clin; Paris, octobre 1988.

15. **Salmon I**, Kiss R, De Witte O, Pasteels JL, Brotchi J, Flament-Durand J: Caractérisation du degré de ploïdie dans une série de 111 astrocytomes. Soc Franç Neuropathologie. Paris, décembre 1990.

16. Vernhes L, **Salmon I**, Depardieu C, Verhest A: Aspiration à l'aiguille fine et diagnostic cytologique de tumeurs malignes primitives multiples. Soc Franç Cytol Clin. Avril 1990.

17. Verhest A, **Salmon I**: Cytologie thyroïdienne exclusive avant décision thérapeutique. 3èmes Journées Francophones de Cytologie, Paris, octobre 1991.

18. De Witte O, **Salmon I**, Kiss R, Flament-Durand J, Pasteels JL, Brotchi J: Détermination du taux de ploïdie dans les gliomes comme facteur pronostique de survie. Société de Neurochirurgie de Langue Française, Paris, décembre 1991.

19. Rypens F, Avni F, Matos C, **Salmon I**, Closset J: Masse interfessière d'étiologie inhabituelle chez un garçon de douze ans. 42ème Journée Française de Radiologie. Paris, octobre 1994.

20. **Salmon I**: Apport de la cytologie au diagnostic des tumeurs cérébrales. Journée de Pathologie. Lille, mai 1995.

21. Noterman J, **Salmon I**, De Witte O, Levivier M, Brotchi J: Les tumeurs des nerfs périphériques. A propos de 19 cas. 45ème Congrès de la Société de Neurochirurgie de Langue Française. Argentine, septembre 1995.

22. De Witte O, Levivier M, Violon P, **Salmon I**, Brotchi J, Goldman S: Intérêt de la tomographie par émission de positons dans l'évaluation pronostique des gliomes de bas grade. Société de Neurochirurgie de Langue Française. Paris, décembre 1995.

23. Van Bogaert P, Levivier M, Wetzburger C, David P, **Salmon I**, Goldman S: Cure chirurgicale d'une épilepsie symptomatique d'une dysplasie corticale focale: intérêt du PET au FDG. Réunion Conjointe de la Ligue Française Contre l'Epilepsie et de la Société Neurophysiologique Clinique de Langue Française. Paris, mars 1996.

24. Sokolow Y, Nagy N, Jansens JL, Capello M, Delbecq K, **Salmon I**, Rocmans P: Importance de l'analyse extemporanée dans la décision chirurgicale en cas de cancer thyroïdien. Vème Congrès de l'Association Francophone de Chirurgie Endocrinienne. Nantes, juin 1997.

25. Nagy N, Decaestecker C, Sokolow Y, Danguy A, Gabius HJ, Rocmans P, Kiss R, **Salmon I**: Identification des lésions thyroïdiennes préneoplasiques par l'étude quantitative de la mesure histochemique des protéines liant le galactose. Vème Congrès de l'Association Francophone de Chirurgie Endocrinienne. Nantes, juin 1997.

26. DeWitte O, Levivier M, Wikler D, David P, Vandesteene A, Pirotte B, **Salmon I**, Goldman S, Brotchi J : Résection volumétrique des gliomes guidée sous la TEP et l'IRM. Société de Neurochirurgie de Langue Française. Paris, décembre 1997.

Internationals

27. Van Regemorter G, **Salmon I**. Zoladex versus orchiectomy in prostate cancer. Int Symp Endocr Ther. Monaco, November 1988.
28. Vanden Bossche M, **Salmon I**, Haddad S, Rahier I, Flament J, Schulman CC: Vesicoureteric reflux: endoscopic correction by injection of teflon and collagen, an experimental and pathological study. 24Th Congress of European Society for Surgical Research. Brussels, February 1989.
29. **Salmon I**: Fine-needle aspiration of thyroid. British Division of the Int Acad Pathol, Bruxelles, April 1989.
30. **Salmon I**, Kiss R, Andry G, Dor P, Pasteels JL, Verhest A: Quantitative morphonuclear cell image analysis of benign and neoplastic thyroid tissues. 17th Meeting of the European Federation of Cytology Societies. Flims-Waldhaus, avril 1989.
31. **Salmon I**, Van Gansbeke D, de Launoit Y, Rahier I, Merle S, Andry G, Dor P, Verhest A, Kiss R: Quantitative morphonuclear cell image analysis of benign and neoplastic thyroid tissues. First Conf of the Europ Soc for Anal Cell Pathol, Schloss-Elmau, Germany, Nvovember 1989. Anal Cell Pathol 1989 ;1:296 (abstract 81) (invited oral lecture as Chairman).
32. **Salmon I**, Kiss R, Franc B, Heimann R, Verhest A: Comparison of cytomorphonuclear features from normal, benign and neoplastic thyroid tissues seen through digital cell image analysis. 38th Congr Am Soc Cytology. Washington, November 1990 (poster). Anal Quant Cytol Histol 34: 728 (abstract 22); 1990.
33. **Salmon I**, Pauwels O, Gras S, Kiss R: Influence of gastrin, estradiol and gonadoliberin on HCT-15 and LoVo in vitro culture human colorectal neoplastic cell proliferation and differentiation. 1991 Annual AACR Meeting (Houston), abstract 316 (poster), Proceedings of the AACR, p. 53; 1991.
34. **Salmon I**, Kiss R: Characterization of the ploidy level in 477 tumors of the central and peripheric nervous system. 1992 Annual AACR Meeting (San Diego), abstract 1546 (poster), Proceedings of the AACR, p. 258; 1992.
35. **Salmon I**, Kiss R, Segers V, Carroyer JM, Levivier M, Pasteels JL, Brotchi J, Flament-Durand J: Characterization of nuclear size, ploidy, DNA histogram type, and proliferation index in 79 nerve sheath tumors. 4th Europ Congr of Neuropathology. Berlin, July 14-18 (poster). Clin Neuropathol 1992;11:181.
36. **Salmon I**, Kiss R, Levivier M, Rummelink M, Pasteels JL, Brotchi J, Flament-Durand J: Characterization of the nuclear DNA content, the proliferation index and the nuclear size in a series of 181 meningiomas. 4th Europ Congr of Neuropathology. Berlin, July 14-18 (poster). Clin Neuropathol 1992;11:214.
37. Levivier M, Goldman S, Bidaut L, Luxen A, Stanus E, Brucher JM, **Salmon I**, Brotchi J, Hildebrand J: FDG-PET in the planning of stereotaxic brain biopsies. Am Acad Neurol; 44th Annual Meeting. San Diego - California. Neurology 42 (supl 3), abstract 190s, p 191, 1992.
38. **Salmon I**, Kiss R: Ploidy measurements in 668 tumors from the peripheric and central nervous systems. 1993 Annual AACR Meeting (Orlando, FL), abstract 157 (poster), Proceedings of the AACR, p. 27; 1993.

39. **Salmon I**: Use of image cytometry for characterizing biological heterogeneity and aggressiveness in human brain tumors. Special Pathology Research Seminar of the Department of Neuropathology, University of Virginia, Charlottesville, December 1993.
40. Camby I, **Salmon I**, Kiss R: Relationship between ploidy level and clone architecture pattern in 12 human brain tumor cell lines. 1994 Annual AACR Meeting (San Francisco, CA), abstract 133, Proc Am Ass Cancer Res 1994;35:23.
41. **Salmon I**, Camby I, Gras T, Kiss R: Characterization of heterogeneity in human adult astrocytic tumors. 1994 Annual AACR Meeting San Francisco, CA), abstract 483, Proc Am Ass Cancer Res 1994;35:81.
42. **Salmon I**, Kiss R: The diagnostic and prognostic values of DNA ploidy determination in human tumors of the central and peripheral nervous system. Conférence sur invitation (ainsi que Chairman d'une session) présentée au « 3rd Conf Eur Soc Anal Cell Pathol » (Grenoble, France). abstract 109. Anal Cell Pathol 1994;6:220.
43. Patay Z, Louryan S, **Salmon I**, Balériaux D: MR imaging of epidural carcinomatous infiltrations: the "Curtain Sign". 20th Congress of the European Society of Neuroradiology. Nancy, June 14-18, 1994.
44. Remmekink M, **Salmon I**, Cras P, Pasteels JL, Brotchi J, Kiss R: Chromatin pattern and DNA ploidy level characterization in ependymomas and choroid plexus tumors. First Congress of the Europ Assoc for Neuro-Oncology (Maastricht, October 15-18, 1994), abstract 210, J Neuro-Oncol 1994;21: 53.
45. **Salmon I**, Rorive S, Rombaut K, Pirotte B, Haot J, Brotchi J, Kiss R: The diagnostic information contributed by quantitative chromatin pattern description in stereotactic biopsies from astrocytic tumors. First Congress of the Europ Assoc for Neuro-Oncology (Maastricht, October 15-18, 1994), abstract 47, J Neuro-Oncol 1994;21:12.
46. Kiss R, **Salmon I**, Camby I, Dewitte O, Brotchi J, Pasteels JL: Is a high level of aneuploidy in tumors of the central and peripheral nervous system related to a tumor's aggressiveness or to its age ? First Congress of the Europ Assoc for Neuro-Oncology (Maastricht, October 15-18, 1994), abstract 95, J Neuro-Oncol 1994;21:24.
47. **Salmon I**, Kiss R: DNA ploidy level assessments by means of image cytometry in 95 human brain metastases as opposed to 752 primitive nervous tumors. First Congress of the Europ Assoc for Neuro-Oncology (Maastricht, October 15-18, 1994), abstract 227, J Neuro-Oncol 1994;21:57.
48. Camby I, **Salmon I**, Darro F, Danguy A, Brotchi J, Pasteels JL, Kiss R: Characterization of the influence of 20 anti-hormone and/or anti-growth factor antibodies on the regulation of glioma cell proliferation in vitro. First Congress of the Europ Assoc for Neuro-Oncology (Maastricht, October 15-18, 1994), abstract 96, J Neuro-Oncol 1994;21:24.
49. Yeaton P, Duckworth C, **Salmon I**, Jones RS, Kiss R, Frierson H: Development of a clinical expert system using image cytometry to stage biliary and ampullary adenocarcinomas. Meetings of the AGA, AASLD at Digestive Disease Week (San Diego, May 14-17, 1995). Gastroenterology 1995;108:A556.
50. Lopes MBS, **Salmon I**, Matte J, Schinohoritis P, Rorive S, Raftopoulos C, Mockel J, Brotchi J, Vance ML, Thorner MO, Laws ER Jr, Kiss R. The use of 26 image cytometry-generated

- variables to characterize biological behavior of pituitary adenomas. Glasgow Meeting, September 1995.
51. Duckworth C, DePrez C, Rombaut K, DeDecker R, **Salmon I**, Kiss R, Yeaton P. Quantitative assessment of PNA and CEA staining in colorectal adenocarcinoma. American College of Gastroenterology; 60th Annual Scientific Meeting, October 16-18, New York, 1995.
52. Danguy A, Camby I, **Salmon I**, Kiss R. Lectin histochemistry of astrocytic tumors and in-vitro characterization of lectin-induced alterations on the proliferation of human astrocytic tumor cell lines. 9th International Conference on Diagnostic Quantitative Pathology, Heidelberg, October 26-28, 1995.
53. Lopes MB, **Salmon I**, Nagy N, Decaestecker C, Laws ER, Kiss R. Image cytometric analysis of gonadotroph adenomas. 72nd Annual Meeting of the American Association of Neuropathologists, Inc. Vancouver, British Columbia, Canada, June 11-16 (1996). Abstract 89, J Neuropathol Exp Neurol. 1996;55:627.
54. Decaestecker C, Lopes MB, Gordower L, Cras P, Martin JJ, Kiss R, Vandenberg S, **Salmon I**. Characterization of the chromatin pattern and DNA ploidy in oligodendrogliomas, astrocytomas, and mixed oligo-astrocytomas. 72nd Annual Meeting of the American Association of Neuropathologists, Inc. Vancouver, British Columbia, Canada, June 11-16 (1996). Abstract 198, J Neuropathol Exp Neurol. 1996;55:654.
55. DeWitte O, Goldman S, Violon P, **Salmon I**, Levivier M, Brotchi J. Prognostic value of FDG uptake in low grade gliomas. Am Ass Neurol Surgeons. Mineapolis, April 1996.
56. Camby I, **Salmon I**, Danguy A, Brotchi J, Martinez J, Kiss R. In vitro characterization of the gastrin- and neurotensin-induced modifications in the cell proliferation rate of human astrocytic tumors. XIII th International Congress of Neuropathology. Perth. Australia, September 7-12, 1997.
57. Decaestecker C, Camby I, DeWitte O, Brotchi J, Kiss R, **Salmon I**. Identification of high versus lower risk clinical subgroups in adult patients with World Health Organization (WHO) grade II and III supratentorial astrocytic tumors. XIII th International Congress of Neuropathology. Perth. Australia, September 7-12, 1997.
58. Decaestecker C, Lopes MB, Gordower L, Cras P, Martin JJ, Kiss R, Vandenberg SR, **Salmon I**. Determination of the proportion of oligodendroglial and astrocytic tumors cells in mixed oligo astrocytomas by the computer-assisted microscope analysis of Feulgen-stained nuclei. XIII th International Congress of Neuropathology. Perth. Australia, September 7-12, 1997.
59. Decaestecker C, Camby I, **Salmon I**, Kiss R. The quantitative chromatin pattern description in Feulgen-stained nuclei contributes significant additional diagnostic and prognostic information to conventional histopathological grading in adult supratentorial astrocytic tumors. 5th Congress of the European Society for Analytical Cellular Pathology. Oslo. Norway. May 25-29, 1997.
60. Rommens J, David P, **Salmon I**, Roger T, Balériaux D. Intraventricular rhabdoid tumor: first case report in a young adult. ASNR / ASHNR. Toronto, May 1997.
61. François C, Decaestecker C, Petein M, Van Ham Ph, Danguy A, **Salmon I**, van Velthoven R, Kiss R. Morphometric-, chromatin pattern- and DNA ploidy-related information submitted to artificial intelligence methods of data analysis to improve accuracy in nuclear grading of renal cell carcinoma. 5th Congress of the European Society for Analytical Cellular Pathology. Oslo. Norway. May 25-29, 1997.

62. Camby I, DeHauwer C, Pirotte B, Van Ham Ph, Brotchi J, **Salmon I**, Kiss R. Gastrin influences growth and motility of human astrocytic tumor cell lines. Swiss Society of Neuropathology. XVII International Winter Meeting. St Moritz, March 1998.
63. Camby I, Darro F, Decaestecker C, **Salmon I**, Martinez J, Kiss R. Influence of natural and synthetic bombesin-related compounds on the in vitro growth of human astrocytic tumor cell lines. American Association of Cancer Research Annual Meeting. New Orleans. March 28-April 1, 1998.
64. Bier JC, Caroyer JM, **Salmon I**, Zegers de Beyl D. Encephalomyelopathy associated with monoclonal gammopathy: a case report. Annual Meeting of the American Association of Neurology. Mineapolis, April 1998.
65. Darro F, Camby I, Burchert M, **Salmon I**, Gabius HJ, Kiss R. In vitro galectin-1 significantly modulates cell kinetics and the motility level of the U87 and U373 human glioblastoma cell lines. Abstract 2980. 90th Annual Meeting. American Association for Cancer Research. Philadelphia. April 10-14, 1999.
66. Bronckart Y, Decaestecker C, Darro F, Danguy A, **Salmon I**, Kiss R. Grading dysplasia in colorectal adenomas by means of quantitative binding pattern determination of five lectins. Abstract 3037. 90th Annual Meeting. American Association for Cancer Research. Philadelphia. April 10-14, 1999.
67. Camby I, Schäfer B, Pochet R, **Salmon I**, Kiss R, Heizmann CW, Decaestecker C. S100 calcium-binding proteins are differentially expressed in human astrocytic tumors. European Congress of Cell Biology. Bologna. May 8-11, 1999.
68. Evrard L, Vanmuylder N, **Salmon I**, Herman C, Rooze M, Dourov N, Louryan S. HSP110 is a marker of apoptosis in some physiological and induced conditions. The 3rd International Cell Death Symposium. Madrid. May 6-9, 2000.
69. Camby I, Decaestecker C, Bovin NV, **Salmon I**, Gabius H-J, Kiss R. Detection of distinct changes in binding capacity to saccharide Epitopes for supratentorial astrocytic tumors. XIVth International Congress of Neuropathology. Birmingham. September 3-6, 2000.
70. Camby I, Bruyneel E, Geurts A, Decaestecker C, Sweep F, Brotchi J, Mareel M, Kiss R, **Salmon I**. Do human oligodendroglial and astroglial tumors derive from mature oligodendrocytes and astrocytes, or from precursor glial cells ? XIVth International Congress of Neuropathology. Birmingham. September 3-6, 2000.
71. Camby I, Lefranc F, Bruyneel E, Brotchi J, **Salmon I**, Mareel M, Kiss R. Gastrin-induced modifications of cell motility and invasion processes in rat and human high-grade astrocytic tumors. XIVth International Congress of Neuropathology. Birmingham. September 3-6, 2000.
72. Lasudry J, Nagy N, Noël J-C, Péteïn M, de Dobbeleer G, **Salmon I**. Clinical significance of p53 overexpression and HPV infection in eyelid sebaceous gland carcinoma. European Society of Ophthalmic Plastic and Reconstruction Surgery. Paris. September 14-16, 2000.
73. Oulad Ben Taïb N, David P, Rorive S, **Salmon I**, Brotchi J, De Witte O. Fibrillary astrocytoma presenting as an extra-axial tumor in the cerebellopontine Angle : case report. Société Belge de Neurochirurgie. Pontresina. March 21-23, 2001.
74. Szeifert GT, **Salmon I**, David P, Devriendt D, Desmedt F, Brotchi J., Levivier M.

Simultaneous detection of tumor control and growth in a patient with two cerebral metastases treated with gamma knife radiosurgery. 5th International Stereotactic Radiosurgery Society Congress. Jerusalem. June 4-7, 2001.

75. Szeifert GT, Vandersmissen B, Oulad Ben Taïb N, Balériaux D, **Salmon I**, Brotchi J, Levivier M. Hemorrhage following angiographic confirmation of obliteration of arteriovenous malformation after radiosurgery. 5th International Stereotactic Radiosurgery Society Congress. Jerusalem. June 4-7, 2001.

76. Szeifert GT, Vandersmissen B, Oulad Ben Taïb N, Balériaux D, **Salmon I**, Brotchi J, Levivier M. Hemorrhage following angiographic confirmation of obliteration of arteriovenous malformation after radiosurgery. 5th International Stereotactic Radiosurgery Society Congress. Las Vegas. June 10-13, 2001.

77. Szeifert GT, **Salmon I**, David P, Devriendt D, Simon S, Massager N, Brotchi J, Levivier M. Positive phenotype modification (re-differentiation) in malignant astrocytoma after Gamma Knife Surgery. Congress of Neurological Surgeons 51st Annual Meeting. San Diego. September 29 - October 4, 2001.

78. Carvalho S, Balériaux D, Brotchi J, **Salmon I**, Lefranc F. Thoracic spinal schwannoma. European Association of Radiology. Luxembourg. March 28, 2002.

79. Debelle F, Nortier J, De Prez E, **Salmon I**, Deschodt-Lanckman M, Vanherweghem JL. Inhibition of the Renin-Angiotensin System (RAS) does not prevent renal fibrosis in a rat model of Chinese-Herb Nephropathy (CHN). Abstract 952570. 35th Annual Meeting and Scientific Exposition Submission Program. May 2002.

80. Van Ginckel R, Mortier S, **Salmon I**, Kiss R, Darro F. Validation of a chemotherapy-resistant orthotopic human NSCLC model metastasizing to the brains of athymic mice and quantification of the expression of clinical markers. Toronto-Canada. April 5-6, 2003.

81. Decaestecker C, Rorive S, Catteaux X, Berton A, Bièche I, **Salmon I**. A compilation of microarray gene expression profiles to explore the biological characteristics of low-grade astrocytomas. XVI International Congress of Neuropathology. San Francisco. September 10-15, 2006.

82. **Salmon I**, Maris C, D'Haene N, Bièche I, Decaestecker C. Tenascin-C expression is mostly related to tumor location in low-grade astrocytomas. XVI International Congress of Neuropathology. San Francisco. September 10-15, 2006.

83. Rorive S, Sandras F, Biskri L, Fossion C, Catteau X, Roumeguere T, Vanden Bossche M, Mijatovic T, **Salmon I**. RT-PCR-based UCA1 expression detection in urine samples as non-invasive reliable method for urothelial cancer diagnosis. EORTC-NCI-ASCO Brussels October, 2009.

84. Ferdinande L, Mathieu A, Decaestecker C, Negulescu A M, Cuvelier C A, **Salmon I**, Demetter P. Indoleamine 2,3-dioxygenase expression is an independent prognostic factor in pT1-4N1Mx staged colorectal cancer. Gastrointestinal Cancers Symposium Rabat, January, 2010.

